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ABSTRACT 
ROLE OF GANGLIOSIDE GM3 IN METASTATIC CANCER CELLS WITH 
MACROPHAGE PROPERTIES: EVIDENCE FROM A NEW MOUSE TUMOR MODEL 
Leanne C. Huysentruyt 
Thesis Advisor: Thomas N. Seyfried 
Metastasis is the process by which cancer cells disseminate from the primary neoplasm 
and invade surrounding tissue and distant organs, and is the primary cause of morbidity 
and mortality for cancer patients.  Most conventional cancer therapies are ineffective in 
managing tumor metastasis.  This has been due in large part to the absence of in vivo 
metastatic models that represent the full spectrum of metastatic disease.  Here I identify 
three new spontaneously arising tumors in the inbred VM mouse strain, which has a 
relatively high incidence of CNS tumors.  Two of the tumors (VM-M2 and VM-M3) 
reliably expressed all of the major biological processes of metastasis to include local 
invasion, intravasation, immune system survival, extravasation, and secondary tumor 
formation involving liver, kidney, spleen, lung, and brain.  Metastasis was assessed 
through visual organ inspection, histology, immunohistochemistry, and bioluminescence 
imaging.  The metastatic VM tumor cells also expressed multiple properties of 
macrophages including morphological appearance, surface adhesion, phagocytosis, 
gene expression (CD11b, Iba1, F4/80, CD68, CD45, and CXCR4) and total lipid 
composition (glycosphingolipids and phospholipids).  The third tumor (VM-NM1) grew 
rapidly and expressed properties of neural stem/progenitor cells, but was neither 
invasive nor metastatic.  This thesis research also examined the influence of a gene-
linked up-regulation of the simple ganglioside GM3 in the metastatic VM-M3 tumor.  
Ganglioside GM3 has been shown to have anti-invasive effects through its ability to 
modulate integrins and matrix metalloproteases.  Additionally, GM3 was previously 
shown to be elevated in resting macrophages when compared to activated 
macrophages. The bioluminescent VM-M3 cells (M3/Fluc) contain mostly GM2, GM1, 
and GD1a with undetectable levels of GM3.  Additionally, the M3/Fluc cells express 
GalNAc-T, a key enzyme for the synthesis of complex gangliosides from GM3, the 
precursor used for complex ganglioside biosynthesis.  Stable transduction of the 
M3/Fluc tumor with a lentiviral vector containing a cDNA sequence targeting the 
GalNAc-T gene (Fluc-TNG), resulted in a knock-down of GalNAc-T expression and an 
up-regulation of GM3 compared to the control (Fluc-csh) transduced M3/Fluc tumor 
cells.  In vivo, the Fluc-TNG cells were significantly less invasive when implanted in the 
brain and less metastatic when implanted in the flank when compared to the control 
Fluc-csh tumors.  My data indicate that spontaneous brain tumors can arise from 
different cell types in VM mice and that the ganglioside GM3 can inhibit invasion and 
metastasis in metastatic cancer cells with macrophage properties.  The new VM tumor 
model will be useful for defining the biological processes of cancer metastasis and for 
evaluating potential therapies for tumor management. 
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INTRODUCTION 
 
 
Metastasis 
 
 
Metastasis is the process by which cancer cells disseminate from the primary 
neoplasm, invade surrounding tissue and distant organs. This process involves 
cancer cell detachment from the primary tumor, intravasation into the circulation, 
evasion of immune attack, extravasation at distant capillary beds, and invasion 
and proliferation in distant organs (Chambers et al. 2002; Fidler 2003; Welch 
2006; Duffy et al. 2008; Steeg and Theodorescu 2008).  In addition, the 
metastatic cells establish a microenvironment facilitating colonization 
(angiogenesis and further proliferation), resulting in macroscopic malignant 
secondary tumors (Chambers et al. 2002; Fidler 2003; Steeg 2006; Welch 2006).  
Metastatic cells preferentially invade those organs (lymph nodes, lung, liver, 
brain, bone, pleura and peritoneum) that promote tumor cell growth and survival 
consistent with the ‘seed and soil’ hypothesis (Paget 1889; Munzarova and 
Kovarik 1987; Fidler 2003; Duffy et al. 2008; Steeg and Theodorescu 2008).  The 
metastatic and invasive potential of cancer cells is often correlated with 
abnormalities in phospholipids and in cell-surface glycolipids, which contribute to 
tumor progression (Yates et al. 1979; Campanella 1992; Sliva et al. 2000; 
Mitsuzuka et al. 2005).  Hence, aberrant cellular migration and proliferation 
characterize the metastatic phenomenon.  
 
Role of macrophages in tumor progression 
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Macrophages arise from immature monocytes in the bone marrow that migrate 
into tissues and undergo their final differentiation into resident tissue 
macrophages.  Macrophages play a role in many biological processes to include 
tissue remodeling, inflammation, and the immune response (Burke and Lewis 
2002a).  It has been well established that macrophages are a major component 
of many malignant tumors (van Ravenswaay Claasen et al. 1992).  These tumor-
associated macrophages (TAMs) play a large role in tumor progression.  TAMs 
release proteases that break down the basement membrane, secrete factors that 
guide tumor cells toward blood vessels, up-regulate angiogenic growth factors 
and secrete factors that suppress anti-tumor functions of immune cells.  
Therefore, TAMs can influence tumor progression through promoting invasion, 
angiogenesis, metastasis and immunosuppression (Lewis and Pollard 2006). 
 
Animal models of metastatic cancer 
Tumor cell metastasis is the primary cause of morbidity and mortality for cancer 
patients (Chambers et al. 2002; Steeg 2006).  While many primary tumors can be 
treated with conventional therapies, few treatments are effective against 
metastatic disease (Fidler and Hart 1982; Chambers et al. 2002; Steeg 2006).  
The lack of effective therapies for metastasis has been due in large part to the 
absence of in vivo metastatic models that represent the pathophysiology and 
biological progression of metastatic disease (Paris and Sesboue 2004; Steeg 
2006; Huysentruyt et al. 2008).  For example, experimental metastasis models 
require injection of tumor cells directly into the host’s circulation, thus bypassing 
 3 
the early stages of metastasis prior to local invasion and intravasation (Paris and 
Sesboue 2004; Khanna and Hunter 2005; Steeg 2006).  While spontaneous 
models express more steps of metastasis than experimental models, many of 
these require implantation of tumor cells as xenographs into immune 
compromised animals.  The use of immune compromised animals is a drawback 
because tumor cell evasion of the host’s immune system is a key rate-limiting 
process in metastatic spread (Chambers et al. 2002; Khanna and Hunter 2005; 
Steeg 2006).  Spontaneous metastasis models also do not reliably produce 
secondary lesions, while the metastatic spread in genetically engineered models 
is often sporadic and of long latency (several months) (Hoffman 1999; Chambers 
et al. 2002; Khanna and Hunter 2005; Steeg 2006).  Finally, current metastatic 
mouse models do not naturally produce brain metastasis, a frequent occurrence 
in many human metastatic cancers (Schackert and Fidler 1988; Yang et al. 1999; 
Khanna and Hunter 2005).  These shortcomings and limitations of current in vivo 
models hinder progress in developing new therapies for metastatic cancer.   
 
VM tumor model 
I have developed a novel preclinical model of invasive/metastatic cancer in the 
VM mouse strain that expresses all hallmarks of human systemic metastatic 
cancer.  The VM model consists of three tumors that arose spontaneously in the 
brains of VM mice.  While spontaneous tumors of the central nervous system 
(CNS) are rare in mice and occur with an incidence of approximately 0.05% 
(Morgan et al. 1984), the VM mouse strain is unique in that spontaneous CNS 
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tumors arise in this strain at a relatively high incidence of about 1.5%(Fraser 
1986).  Although many spontaneous primary tumors arising in the VM mouse 
brain were described previously as astrocytomas (Fraser 1986), one described 
VM brain tumor was not of neural origin and had metastatic properties when 
grown outside the brain (El-Abbadi et al. 2001).  I prepared cell lines from the 
three spontaneous VM tumors that were identified as VM-M2, VM-M3, and VM-
NM1.   
 
The VM-M2 and the VM-M3 tumors were highly invasive when grown in the brain 
and metastasized to multiple organ systems when grown subcutaneously in the 
flank or orthotopically in the brain.  The VM-NM1 tumor was also malignant, but 
was not invasive in brain and did not metastasize when grown subcutaneously or 
orthotopically.  
 
Gangliosides 
Gangliosides are a family of sialic-acid containing glycosphingolipids that are 
present in the plasma membrane of most vertebrate cells and highly enriched in 
the central nervous system (Derry and Wolfe 1967; Fishman and Brady 1976; 
Ledeen and Yu 1982; Hakomori 1986).  These molecules contain an 
oligosaccharide head group attached to a lipophilic ceramide, consisting of a 
sphingosine base and a long-chain fatty acid (Leeden 1985).  The 
oligosaccharide head group is composed of combinations of glucose, galactose, 
N-acetylgalactoseamine, and N-acetylglucosamine (Yogeeswaran et al. 1972).  
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Gangliosides are anchored into the outer leaflet of the plasma membrane 
through the ceramide moiety and the oligosaccharide head group projects into 
the extracellular environment (Figure 21).  These glycosphingolipids are a 
structurally diverse group of molecules due to the different sialic acid species, 
various combinations of oligosaccharides and differences in the length of the 
fatty acid (Ledeen and Yu 1982; Ando and Yu 1984; Sonnino et al. 1984). 
 
Ganglioside biosynthesis 
Ganglioside biosynthesis occurs in the Golgi by a step-wise addition of 
monosaccharides to a ceremide moiety.  This occurs through the action of a 
multi-glycosyltransferase system, where the product of one transferase serves as 
the substrate for the next transferase in the pathway (Figure 22) (Roseman 1970; 
Keenan et al. 1974; Yusuf et al. 1984; Yu et al. 2004).  Following synthesis, 
gangliosides are packaged into vesicles in the Golgi and then fuse with the 
plasma membrane (Young et al. 1992). 
 
Ganglioside biosynthesis occurs in four metabolic pathways, the “asialo”, “a”, “b”, 
and “c” pathways (Figure 22).  The pathways are characterized based upon the 
number of sialic acid residues on the internal galactose.  Gangliosides that are 
synthesized through the asialo pathway do not contain a sialic acid on the 
terminal galactose, however, gangliosides synthesized through the “a”, “b”, and 
“c” pathways have one, two, and three sialic acids, respectively (Pohlentz et al. 
1988; Iber et al. 1989; Iber and Sandhoff 1989).  LacCer is converted to GM3, 
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the precursor for ganglioside synthesis in the “a” pathway, by the addition of a 
sialic acid.  This reaction is catalyzed by the enzyme GM3-synthase, which adds 
a single sialic acid to the terminal galactose of LacCer.  GD3 and GT3, the 
precursors of the “b” and “c” pathways, respectively, are produced by the addition 
of sialic residues to GM3 (Figure 22) (Iber et al. 1991; Nakayama et al. 1996). 
 
Ganglioside function and role in tumorigenesis and metastasis 
The ganglioside head group modulates various cell surface processes to include 
growth, migration, adhesion, and signaling (Bai and Seyfried 1997; Yates and 
Rampersaud 1998; Aoki et al. 2004).  Ganglioside composition and distribution 
undergoes marked changes during oncogenic transformation. These molecules 
may influence tumor progression through modulation of cellular division, 
adhesion, angiogenesis and invasion (Bremer et al. 1986; Noll et al. 2001; 
Hakomori 2002; Fujimoto et al. 2005; Toledo et al. 2005; Abate et al. 2006; 
Mukherjee et al. 2008).  There is also evidence for the role of gangliosides in 
metastasis.  Interestingly, cells with a metastatic phenotype contain more of the 
complex gangliosides than non-metastatic cells (Kawamura et al. 2001; 
Mitsuzuka et al. 2005).  Additionally, GM3 has been shown to have anti-invasive 
effects through it’s ability to modulate matrix metalloproteases and integrins, 
molecules involved in extracellular matrix degradation and adhesion, respectively 
(Wang et al. 2003; Mitsuzuka et al. 2005).  The previous studies examining the 
effects of GM3 on invasion/metastasis have focused only on the effects produced 
by exogenous addition of GM3 and transient up-regulation of GM3.  To our 
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knowledge, no one has stably genetically up-regulated endogenous GM3 
expression in invasive/metastatic cells and examined it’s effects on in vivo 
metastasis (Kawamura et al. 2001; Fujimoto et al. 2005; Mitsuzuka et al. 2005).  
In this study, I up-regulated GM3 content in the highly metastatic bioluminescent 
VM-M3 cells (M3/Fluc) by stable knockdown of the GalNAc-T gene, the enzyme 
responsible for conversion of GM3 to GM2 in the “a” pathway allowing us to 
examine to role of GM3 when endogenously up-regulated and in vivo. 
 
Glycosynapse 3  
Glycosynapse 3 is a membrane microdomain complex consisting of GM3, the 
proteolipid/tetraspanin CD9, and alpha3beta1 integrin (Mitsuzuka et al. 2005).  
These microdomains are capable of controlling cell adhesion and 
migration/invasion (Ono et al. 2001; Mitsuzuka et al. 2005; Toledo et al. 2005).  
Glycosynapse 3 is “organized” in non-invasive and non-metastatic human 
bladder tumor cells, but is “disorganized” in highly invasive and metastatic 
bladder tumor cells due to the absence of GM3 (Mitsuzuka et al. 2005).  Thus, 
GM3 plays a fundamental functional role in the glycosynpase.  For example, high 
levels of GM3 promotes the interaction of alpha3 integrin with CD9 resulting in 
stablization of glycosyapse 3 (Mitsuzuka et al. 2005).  Disorganization of this 
complex through a reduction in GM3 is proposed to underlie the invasive and 
metastatic behavior of human tumor cells (Mitsuzuka et al. 2005) 
 
Gangliosides in macrophages 
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Macrophages are the major differentiated cells of the mononuclear phagocyte 
system (Burke and Lewis 2002a).  These cells are widely distributed throughout 
the body and many reside in lymphoid organs, liver, lung, gastrointestinal tract, 
CNS, serous cavities, bone and skin (Burke 2002).  In response to tissue injury 
or disease, a macrophage goes from a resting to an activated state (Burke 2002).  
Upon activation, normal macrophages can express several hallmarks of 
metastatic tumor cells.  For example, activated macrophages extravasate from 
the circulation into inflamed or diseased tissue where they proliferate and are 
capable of phagocytosis while establishing a microenvironment to facilitate 
angiogenesis and wound healing (Sunderkotter et al. 1994b; Bellingan et al. 
1996; Seyfried 2001a; Burke 2002).  Interestingly, macrophage activation is also 
associated with changes in ganglioside content and distribution.  For example, 
resting mouse macrophages contain predominately GM3, GM1, and GD1a, 
whereas activated mouse macrophages contain GM2, GM1, GD1a and 
GD1alpha (Yohe et al. 1985b; Macala and Yohe 1995; Yohe et al. 1997; Ecsedy 
et al. 1998b).  It is important to note the reduction of ganglioside GM3 upon 
macrophage activation (Yohe et al. 1985a).  As mentioned above, GM3 is 
thought to have anti-invasive and anti-metastatic effects.  As shown below, the 
highly metastatic, VM-M2 and VM-M3 tumor cells of macrophage origin do not 
contain GM3 in contrast to the non-metastatic VM-NM1 tumor cells of neural 
stem cell origin that contain high levels of GM3 (Huysentruyt et al. 2008).  
Therefore, the differences in GM3 content may be related to the differences in 
cellular origin.  I hypothesize that endogenous up-regulation of GM3 in the 
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metastatic VM-M3 cells, will switch from an “activated” to a “resting” phenotype 
and therefore have a decrease in invasive and metastatic potential. 
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MATERIALS AND METHODS 
 
 
Mice 
 
Mice of the VM/Dk (VM) strain were obtained as gifts from G. Carlson (McLaughlin 
Research Institute, Great Falls, Montana) and H. Fraser (University of Edinburgh, 
Scotland).  All VM mice used in this study were housed and bred in the Boston College 
Animal Care Facility using husbandry conditions as described previously (Ranes et al. 
2001).  VM mice were housed in plastic cages with Sani-chip bedding (P.J. Murphy 
Forest Products Corp., Montville, NJ) and fed ad libidium with PROLAB RMH3000 lab 
chow (LabDiet, Richmond, IN) on a 12 hour light/12 hour dark cycle.  The animal room 
was maintained at 22°C+ 1°C.  All animal procedures were in strict accordance with the 
NIH Guide for the Care and Use of Laboratory Animals and were approved by the 
Institutional Animal Care Committee. 
 
Origin of VM tumors 
 
The VM-M2, the VM-M3, and the VM-NM1 tumors arose spontaneously in the cerebrum 
of three adult VM mice, two males and a female.  The tumors were detected during 
routine examination of the VM mouse colony over a period of several years (1993-
2000).  Each tumor-bearing mouse expressed cranial swelling and appeared lethargic 
with the males also expressing priapism.  These symptoms appeared for only about 1-3 
days before morbidity.  The tumors were grossly identified in the cerebrum as poorly 
defined masses (about 3 x 1 x 1 mm) similar to those described previously for other 
spontaneous tumors in the VM mouse brain (Fraser 1986; El-Abbadi et al. 2001).  In 
order to preserve in vivo viability, each tumor was immediately resected and implanted 
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intracerebrally (i.c.) into host VM mice as described below.  As soon as cranial domes 
appeared, the tumors were passaged again into several host VM mice.  After a total of 
three i.c. passages, the tumors were grown subcutaneously (s.c.) and cell lines were 
prepared from each tumor as described below.  All cell lines were cultured under 
identical conditions to reduce environmental variability. 
 
Intracerebral and subcutaneous tumor implatation 
 
The VM tumors were implanted either i.c. or s.c. as we previously described (Ranes et 
al. 2001).  For i.c. implantation, VM mice were anaesthetized with Avertin (0.1mL/ 10g 
body weight), their heads were shaved and swabbed with 70% ethanol under sterile 
conditions.  A midline incision was made on the head.  A 1 mm burr hole was made, 
using and electric drill, over the right parietal region.  Small tumor pieces (1 mm3, 
estimated using a 1 mm x 1 mm grid) from a donor VM tumor were implanted into the 
right cerebral hemisphere of anesthetized recipient VM mice using a trocar.  The skin 
edges were then immediately fused together using collodion (JT Baker, Inc, 
Phillipsburg, NJ).  For s.c. implantation, VM mice were anaesthetized with Isoflurane 
(Halocarbon, River Edge, NJ), and the tumor was implanted by a s.c. injection of 0.1 ml 
of small tumor pieces suspended in 0.2 ml PBS by use of a 1 cc tuberculin syringe and 
a 18-gauge needle into the right flank.  All mice recovered from their surgical procedure 
and were returned to their cages when they became fully active. 
 
In vivo and in vitro growth analysis 
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In vivo growth measurements were determined from the VM-M3 and VM-NM1 tumors 
grown in the brain. Adult VM mice were implanted i.c. with small tumor fragments as 
described above.  After nine days of growth, the mice were sacrificed and the whole 
brain, containing tumor, was weighed.  These brain weights were then compared with 
those of sham-operated mice.  Tumor growth was assessed as the difference in mean 
brain weights between the sham-operated mice and the tumor bearing mice.  This 
approach was used because the highly invasive behavior of the VM-M2 and VM-M3 
tumors prevented their complete surgical resection from surrounding brain tissue.  This 
method for measuring in vivo growth is also more accurate and quantitative than 
volumetric measurements from flank grown tumors, especially for the metastatic VM 
tumors, which are not encapsulated and grow into the underlying muscle tissue of the 
flank.  For in vitro growth analysis of the VM-M2, VM-M3, and the VM-NM1 cell lines, 
approximately 5 x 103 cells were seeded in a 96-well plate and cultured as described 
below.  Cells were analyzed 24, 48 and 72 hrs after seeding using the ViaLight® Plus 
Kit (Cambrex, East Rutherford, NJ), and florescence was measured using a microplate 
reader (SpetraMax, M5; Molecular Devices, CA).  
 
 
Histology 
 
Brain tumor samples were fixed in 10% neutral buffered formalin (Sigma) and 
embedded in paraffin.  The brain tumor samples were sectioned at 5 µm, were stained 
with haematoxylin and eosin (H & E) at the Harvard University Rodent Histopathology 
Core Facility (Boston, MA), and were examined by light microscopy as we previously 
described (Mukherjee et al. 2002). 
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Metastasis analysis 
Metastatic spread of VM tumors was analyzed in host VM mice following s.c 
implantation of VM tumor fragments or cell lines as described above.  Metastasis to 
liver, spleen, and kidney was confirmed by visual inspection of these organs for the 
presence of gross tumor nodules. In addition to visual inspection, metastasis was also 
determined from histological (H&E staining), immunohistochemical (Iba1 
immunostaining), and bioluminescent analysis as described below. 
 
Iba-1 staining for microglia/macrophages 
The immunohistochemical procedures for Iba1 staining were similar to those 
previously described (Drage et al. 2002; Mukherjee et al. 2002).  After 
deparaffinization, rehydration, and washing, the tumor sections were heat treated 
(95oC) in antigen unmasking solution (Vector Laboratories Inc., Burlingame, CA) 
for 30 min.  Tissue sections were treated with Iba-1 (rabbit polyclonal, 1:1000, gift 
from Yoshinori Imai, Japan) in blocking buffer overnight at 4oC, followed by a 
biotinylated anti-rabbit IgG at 1:100 dilution (Vector Laboratories, Inc., Burlingame, 
CA).  The sections were then treated with avidin-biotin complex followed by 3-3' 
diaminobenzidine as substrate for staining according to the manufacturer's 
directions (Vectastain Elite ABC kit; Vector Laboratories Inc.).  Sections were 
counter stained with methyl green and mounted.  Corresponding tissue sections 
without primary antibody served as negative controls.  Samples were examined by 
light microscopy as described above. 
 
Cell lines and culture conditions 
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Cell lines were established from each flank-grown VM tumor as previously described 
(Seyfried et al. 1992).  Briefly, tumor tissue was removed from the mice and was 
transferred to a Petri dish containing Dulbecco’s Modified Eagle medium (DMEM, 
Sigma, St. Louis, MO) with high glucose (25 mM) supplemented with 10% fetal bovine 
serum (FBS, Sigma) and 50 µg/ml penicillin-streptomycin (Sigma).   The tumor tissue 
was minced thoroughly to obtain a cell suspension.  1 ml of the cell suspension was 
then seeded into a tissue culture flask containing DMEM (25mM glucose, 10%FBS) The 
VM tumor cells were evaluated after a minimum of eight passages to insure that the 
cells lines were uniformly homogeneous. The macrophage RAW 264.7 and the 
astrocyte C8-D30 (Astrocyte type III clone, AC) cell lines were purchased from 
American Type Culture Collection (Manassas, VA).  The cell lines were grown in cell 
culture flasks (Corning, Inc., Corning, NY) in DMEM (25mM glucose, 10% FBS).  The 
cells were cultured in a CO2 incubator with a humidified atmosphere containing 95% air 
and 5% CO2 at 37°C.  At confluency, cells were removed from the flasks with a cell 
scraper and were passed to a new culture flask.   
 
Transduction of tumor cells 
The lentiviral vector CSCGW2-Fluc-IG was derived from CSCGW by deleting all 
promoter elements from the U3 region in the 3'LTR and inserting a firefly luciferase 
(Fluc)-IRES-EGFP cassette under control of the CMV promoter as previously described 
(gift from Miguel Sena-Esteves)(Sena-Esteves et al. 2004).  Lentiviral vector stocks 
were produced with titers of 1x10^8 tu/mL.  One day prior to infection, approximately 
100,000 VM-M3 cells were plated in a 6-well plate in DMEM.  Infection was performed 
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with a multiplicity of infection (MOI) of 100 in a total volume of 1.5 ml of DMEM 
(M3/Fluc).  After 24 hours of incubation, 2.0 ml of fresh medium was added to the well.  
To obtain a clonal cell line, I passed the VM-M3/Fluc cells 3 times and then sorted them 
into a 96-well plate based on EGFP expression using a MoFlo cell sorter (Dako, 
Carpinteria, CA).  
 
In vitro growth analysis with bioluminescent imaging 
For in vitro growth analysis of cells expressing Fluc, approximately 50,000 cells 
were seeded in a 24-well plate and cultured as described above.  Cells were 
analyzed 24, 48, 72, and 96 hours after seeding using the Xenogen IVIS system 
(Caliper LS, Hopkington, MA).  For imaging, 20µl of a 300 µl/ml D-luciferin 
(Caliper LS) solution was added to each well and the plates were imaged for 3 
minutes as described below.  Following imaging, the media was changed in the 
well and fresh DMEM was added. 
 
Bioluminescent imaging 
The M3/Fluc, Fluc-csh, or Fluc-TNG cells were implanted s.c. into a VM mouse as 
described above.  The resulting s.c. tumor was used as donor tumor tissue and 
implanted s.c. or i.c. into recipient VM mice as described above.  Mice were imaged with 
the Xenogen IVIS system (Caliper LS) to record the bioluminescent signal from the 
tumors.  The IVIS Lumina cooled CCD camera system was used for light acquisition.  
Data acquisition and analysis was performed with Living Image® software (Caliper LS).  
For in vivo imaging, mice received an i.p. injection of D-luciferin (50 mg/kg, Caliper LS) 
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and Avertin (0.1 mL/10g).  Imaging times ranged from 30 sec to 10 min, depending on 
the time point needed.  For ex vivo imaging, tissues were excised and placed in a Petri 
dish with 300 µg/ml D-luciferin in PBS, and imaged from 1-6 min depending on the 
tissue. 
 
In vivo invasion assay 
The M3/Fluc, Fluc-csh, or Fluc-TNG tumor was implanted i.c. as described 
above.  Mice were sacrificed at morbidity and the brains were removed.  Each 
tumor bearing brain was cut down the midline and the ipsilateral and contralateral 
halves were imaged ex vivo with 300µg/ml D-luciferin in PBS and imaged from 2-
10 minutes. 
 
Morphology 
All cell lines were cultured under identical culture conditions as described above.  
Pictures were taken at approximately 50% cell confluency with a Cyber-shot digital still 
camera (Sony) attached to a phase-contrast microscope (Nikon).  
 
Phagocytosis assay 
Cell phagocytic capacity was determined by using a modification of a standard 
fluorometric assay (Oda and Maeda 1986).  Fluoresbrite® YG carboxylate microspheres 
(1 µm diameter, Polysciences, Warrington, PA) were opsinized with FBS.  To opsinize 
the beads, 750 µl of FBS and 750 µl of the beads were added to a 1.7 ml conical 
microtube and mixed thoroughly.  The bead/FBS mixture was incubated at 37°C for 8 
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hours with occasional agitation.  The bead/FBS mixture was then centrifuged at 3000 xg 
for 5 minutes and the FBS supernantant was removed.   The bead pellet was 
resuspended in 1.5 ml PBS and vortexed.  This was repeated twice for a total of 3 PBS 
washes and the beads were re-suspended in a final volume of 750 µl of PBS.  The VM-
M3, VM-M3, VM-NM1, RAW 264.7 and AC cells were seeded in 8-well Lab-Tek 
Chambered Coverglass Systems (Nunc, Rochester, NY) and were allowed to adhere in 
DMEM.  The cells were then incubated with 10 µl of the bead solution for 1 hr, and were 
rinsed with DMEM to remove excess beads.  Phagocytosis of beads was detected by 
confocal microscopy (Leica TCS SP2, Wetzlar, Germany) and the cells were 
photographed using Lecia software.   
 
Semiquantitative RT-PCR 
All cell lines were grown under identical culture conditions as described above.  Total 
RNA was isolated from homogenized cell pellets of the control and tumor cell lines 
using the Trizol Reagent (Invitrogen, La Jolla, CA), according to the manufacture’s 
protocol.  RNA concentration and purity was determined by spectrophotometric 
measurements at 260 nm and 280 nm.  Single strand cDNA was synthesized from total 
RNA (3µg) using oligo (dT) primers (Promega, Madison, WI) in a 20µl reaction with 
Moloney murine leukemia virus reverse transcriptase (M-MLV RT, Promega) and was 
used for PCR amplification as we previously described (Abate et al. 2006).  Primers 
were optimized for annealing temperatures and cycle number as we previously 
described (Abate et al. 2006).  Primer sequences and amplicon information for CD68, 
F4/80, β-actin, GalNAc-T and GM3 synthase can be viewed at NCBI (National Center 
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for Biotechnology Information, Pubmed) using accession numbers DQ167574, 
DQ167573, N_M007393, L25885, and AF119416, respectively.  CD11b, Iba1, CD45, 
CXCR4, nestin, SATII, GFAP and NF200 can be viewed using accession numbers 
EF101553-EF101560.  Additional genes examined were CD9 (F 5’-TCC GAT TCG ACT 
CTC AGA CC-3’; R 5’-CTC CAA AGG ACC AGC TAT GC-3’), alpha5 integrin (F 5’-ATG 
GCT CAG ACA TCC ACT CC-3’; R 5’-GCA GAG CCA AAG AAG TCT GG-3’), alpha3 
integrin (F 5’-GGT GCC TAC AAC TGG AAA GG-3’; R 5’-AGG AGG GAA GGT TGA 
TCA GG-3’), beta1 integrin (F 5’-GGT GTC GTG TTT GTG AAT GC-3’; R 5’-ATG ATG 
TCG GGA CCA GTA GG-3’), and MMP9 (F 5’-CTA GAC CCA ACT TAT CCA GAC TC-
3’; R 5’-CAT GCA CTG GGC TTA GAT CAT TC-3’).  PCR products were separated on 
1-1.5% agarose gels containing ethidium bromide and visualized by UV light.  RT-PCR 
was performed on the total RNA of each sample in the absence of reverse transcriptase 
to control for possible DNA contamination.   
 
Real-Time PCR 
cDNA was prepared as described above and ~150 ng was used for quantitative real 
time PCR (QRT-PCR) amplification of Iba1 (F 5’-CAG CAA TGA TGA GGA TCT GC-3’; 
R 5’-CCA GCA TTC GCT TCA AGG-3’), GM3 synthase (F 5’-GCA CTA TGT GGA CCC 
TGA CC-3’, R 5’-ATA GCC GTC TTC GCG TAC C-3’), GalNAc-T (F 5’-CTG GAT GGA 
CTT GGT TTC C-3’; R 5’-AAC GGG CAT AAG TTT CAG C-3’), and β-actin (F 5’- GCG 
CAA GTA CTC TGT GTG G-3’; R 5’- TCA TCG TAC TCC TGC TTG C-3’).  To 
determine QRT-PCR primer efficiencies, QRT-PCR was preformed with serial dilutions 
of cDNA.  QRT-PCR amplification was preformed with RealMasterMix SYBR ROX 
 19 
(Fisher) in an Eppendorf Mastercycler ep realplex2.  Data was analyzed with 
Mastercycler ep realplex software.  Iba1 expression levels were determined by 
normalizing Ct values to β-actin.  GalNAc-T and GM3 synthase were quantitated by the 
Pfaffl method (Pfaffl 2001).  QRT-PCR was performed on the total RNA of each sample 
in the absence of reverse transcriptase to control for possible DNA contamination.   
 
Western blot 
Cells were lysed in ice-cold lysis buffer (Cell Signaling Technology, MA) containing 20 
mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM 
NaPPi, 1 mM a-glycerophosphate, 1 mM Na3VO4, 1 mg/ml leupeptin, and 1 mM 
phenylmethylsufonyl fluoride.  Lysates were then centrifuged at 8,100 x g for 20 min.  
Supernatants were collected and protein concentrations were estimated using the Bio-
Rad DC protein assay.  Approximately 50 mg of total protein from cells were loaded on 
a 12% SDS-polyacrylamide gel (Bio-Rad, CA) and electrophoresed.  Proteins were 
transferred to a PVDF immobilon TM-P membrane (Millipore, MA) for 3 hrs at 4o C and 
the membrane was blocked in 5% nonfat powered milk in Tris-buffered saline with 
Tween 20 (pH 7.6) for 1 hr.  Blots were then probed with Iba-1 primary antibody 
(1:1000) (Abcam, MA) overnight at 4oC with gentle shaking.  The blots were then 
incubated with appropriate whole horseradish peroxidase-conjugated secondary 
antibody at room temperature.  Bands were visualized using enhanced 
chemiluminescence plus system (Amersham, UK).  Blots were re-probed with a β-actin 
antibody used as a loading control and the ratio of Iba-1 to β-actin was analyzed by 
scanning densitometry.  
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Lipid isolation, purification, and quantification 
Total lipids were isolated and purified from lyophilized cell pellets by modified 
procedures previously described (Macala et al. 1983; Seyfried et al. 1984; Hauser et al. 
2004; Kasperzyk et al. 2005).  Briefly, neutral lipids and acidic lipids were separated 
using DEAE-Sephadex (A-25; Pharmacia Biotech, Upsala, Sweden) column 
chromatography.  The neutral lipid fraction contained cholesterol esters, cholesterol, 
ceramide, cerebrosides, phosphatidylethanolamine, phosphatidylcholine, 
sphingomyelin, and neutral glycosphingolipids.  The acidic lipid fraction contained the 
gangliosides, free fatty acids, cardiolipin, phosphatidylserine, phosphatidylinositol, 
phosphatidic acid, and sulfatides.  The gangliosides were separated from the acidic lipid 
fraction by Folch partitioning (Folch et al. 1957) and were treated with mild base (0.15 M 
NaOH) and desalted.  Ganglioside sialic acid was quantified by the gas-liquid 
chromatographic method of Yu and Leeden (Yu and Ledeen 1970).  
 
Ganglioside biosynthesis in cultured tumor cells 
Synthesized gangliosides were isolated and purified from control and tumor cell lines as 
previously described (El-Abbadi et al. 2001). Briefly, the cell lines were seeded into 75-
cm2 tissue culture flasks at approximately equal densities and cultured until 50-60% 
confluent.  Three µCi of 14C-galactose (Sigma, St. Louis, MO) was blown to dryness 
under a stream of nitrogen in a Nitrogen Evaporator (N-evap, South Berlin, MA), 
resupended in 10 ml of DMEM, sterile filtered with a 0.2mm filter (Fisher) and then 
added to the cells.  After 48 hours, the cells were removed from the flask with a cell 
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scraper in PBS and pelleted.  Total lipids were extracted from the radiolabeled cells in 
chloroform: methanol (1: 1 by vol).  The gangliosides were separated from the total 
lipids by Folch partitioning (Folch et al. 1957) and were further purified using DEAE-
Sephadex column chromatography, followed by mild base treatment and desalting as 
described above.  Prior to ganglioside isolation, unlabelled mouse brain gangliosides 
were added as a carrier (El-Abbadi et al. 2001).  The concentration of labeled 
gangliosides was determined by scintillation counting.  
 
High-performance thin-layer chromatography 
All lipids were analyzed by high-performance thin-layer chromatograph (HPTLC) as 
previously described (Macala et al. 1983; Hauser et al. 2004; Kasperzyk et al. 2005).  
Lipids were spotted on 10 x 20 cm Silica gel 60 HPTLC plates (E. Merck, Darmstadi, 
Germany) using a Camag Linomat V auto-TLC spotter (Camag Scientific Inc., 
Wilmington, NC).  An internal standard (oleoyl alcohol) was added to the neutral lipid 
and acidic lipid samples to control for the amount of lipids spotted (Macala et al. 1983; 
Kasperzyk et al. 2005).  Purified lipid standards were purchased from Matreya Inc. 
(Pleasant Gap, PA).  For neutral and acidic phospholipids, the plates were developed to 
a height of 4.5 or 6.0 cm, respectively with chloroform: methanol: acetic acid: formic 
acid: water (35: 15: 6: 2: 1 by volume), and then both were developed to the top with 
hexanes: diisopropyl ether: acetic acid (65: 35: 2 by volume).  For gangliosides, the 
HPTLC plates were developed by a single ascending run with chloroform: methanol: 
water (55: 45: 10 by volume) containing 0.02% calcium chloride.  Neutral and acidic 
phospholipids were visualized by charring with 3% cupric acetate in 8% phosphoric acid 
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solution, followed by heating in an oven at 165°C for 7 minutes.  Gangliosides were 
visualized by autoradiogram.  (Macala et al. 1983; Seyfried et al. 1984; Seyfried et al. 
1994; Denny et al. 2006).   
 
Percent distribution of the individual bands was prefomed by scanning the plates on a 
Personal Densitometer SI with ImageQuant software (Molecular Dynamics) as 
previously described (Kasperzyk et al. 2004).   
 
Neutral glycosphingolipid purification 
Neutral glycosphingolipids were purified from the neutral lipid fraction following DEAE-
Sephadex column chromatography as mentioned above.  Briefly, a 4 ml aliquot of the 
neutral lipid fraction was evaporated under a stream of nitrogen and treated with mild 
base as described above.  The solution was then converted to chloroform: methanol: 
water (8: 4: 3) by the addition of 4 ml of chloroform: methanol (2: 1, by vol).  Folch 
partitioning was then used to separate the neutral glycosphingolipids from the 
saponified phospholipids.  The upper aqueous phase was discarded and the lower 
organic phase was washed once with 1.72 ml of chloroform: methanol: water (3: 48: 47, 
by vol).  The combined lower phases were evaporated under a stream of nitrogen and 
resuspended in 4 ml chloroform: methanol (2: 1, by vol) prior to immunostaining.    
 
Asialo-GM1 immunostaining 
Immunostaining for asialo-GM1 (GA1) was performed as previously described (Saito et 
al. 1985; Ecsedy et al. 1998b).  An aliquot of neutral glycosphingolipids representing 
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approximately 2 mg of the original sample dry weight was used for immunostaining.  
GA1 antiserum was obtained from Dr. Robert Yu, Medical College of Virginia, 
Richmond, VA and diluted 1:40.  Perioxidase-conjugated anti-rabbit IgG secondary 
antibody (1:150, Sigma) was used to visualize GA1. 
 
Knockdown of GalNAc-T expression  
 
MISSION short hairpin RNA (shRNA) lentiviral transductions particles were used 
for the knockdown of the GalNAc-T gene and generation of a control shRNA cell 
line (Sigma).  The lentiviral transduction particles were produced from a 
sequence-verified shRNA lentiviral plasmid vector for the mouse gene.  For 
knockdown of GalNAc-T, a 58bp cDNA sequence targeting the CDS region of the 
gene was used (CCG GCC TGT ACT CCA GCA CCC GAA ACT CGA GTT TCG 
GGT GCT GGA GTA CAG GTT TTT G).  In order to produce a negative control 
cell line, a non-target shRNA containing lentiviral vector was used.  The control 
cDNA (cshRNA) vector contains 4 base pair mismatches within the short hairpin 
sequence to any known mouse gene.  Upon transcription, these cDNA 
sequences form a short hairpin RNA structure that acts as double-stranded RNA, 
activating the RNA interference pathway (RNAi).  Each shRNA construct was 
cloned and sequence verified to ensure a match to the target gene.  One day 
prior to infection, approximately 100,000 M3/Fluc cells were seeded in a 6-well 
plate in complete DMEM (25mM glucose, 10%FBS).  Infection was preformed 
with a MOI of 5 in a total volume of 1.5ml of DMEM using either the shRNA or the 
cshRNA lentiviral vector.  After 24 hours of incubation, 2.0ml of fresh DMEM was 
 24 
added to the well.  The viral particle-containing medium was changed 24 hours 
later and replaced with fresh DMEM.  In order to produce cell lines that stably 
expressed the shRNA sequence, the transduced cells were treated in complete 
media containing puromycin (10ug/ml).  Puromycin was added to the medium 
until resistant colonies could be identified. 
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RESULTS 
 
Growth rates and invasive/metastataic behavior 
The in vitro growth rate of the VM-M2 and the VM-M3 tumor cells was significantly 
slower than that of the VM-NM1 tumor cells (Figure 1).  However, the growth rates were 
similar for the VM-M2 and the VM-M3 tumor cells.  The VM-M3 tumor also grew 
significantly slower than the VM-NM1 tumor in vivo (Table 1).  After 9 days of 
intracerebral tumor growth, the mean wet weight (mg + SEM) of the VM-NM1-containing 
brain (522 + 32 mg) was significantly greater than those of the sham operated VM brain 
(388 + 13 mg) or the VM-M3-containing brain (409 + 15 mg) (P < 0.01).  Relative to the 
sham operated brain that contained no tumor, the weight of the VM-NM1-containing 
brain increased by about 26% and that of the VM-M3-containing brain by only 5%, 
consistent with the in vitro differences in cell proliferation.  The VM-M2 and the VM-M3 
tumors achieved comparable size after approximately 4 weeks and 3 weeks of i.c. 
growth, respectively, which was consistent with the intrinsic difference in their in vitro 
growth rates.   
 
The VM-M2 and the VM-M3 tumors were diffusely invasive into the neural parenchyma 
showing multiple tumor foci in the hippocampal region well in advance of the main tumor 
mass (Figure 2A & B).  The VM-M2 tumor cells invaded through the hippocampal CA2 
region and overlying cerebral cortex (Figure 2A) and the VM-M3 tumor cells invaded as 
streams through the cerebral cortex (arrowhead, Figure 2B).  Both the VM-M2 and VM-
M3 tumors formed multiple tumor foci in advance of the main tumor mass in the 
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hippocampal molecular layer (arrows, Figure 2A & B), and also formed perivascular 
pseudorossettes (Figure 2D & E).  The VM-M2 and VM-M3 tumor cells were 
disorganized, pleomorphic, and contained hyperchromatic nuclei (G & H).  In contrast to 
the VM-M2 and the VM-M3 tumors, the VM-NM1 tumor was non-invasive and formed a 
sharp boundary between the main tumor mass and the neural parenchyma (Figure 2C).  
No tumor foci in advance of the main tumor mass or perivascular pseudorossettes were 
detected in brains containing the VM-NM1 tumor (Figure 2C & F).  The cells of the VM-
NM1 tumor also appeared homogenous in shape with poorly defined cytoplasm (Figure 
2I).  The VM-NM1 tumor was highly malignant and caused morbidity after approximately 
10 days of i.c. growth, consistent with the rapid growth rate of this tumor.  These 
findings indicate that the VM-NM1 tumor differed markedly from the VM-M2 and the VM-
M3 tumors with respect to growth rate, morphology, and invasive behavior.  The 
differences in growth rate among the three tumors following initiation from small tumor 
pieces were also observed following initiation from cultured cells.  However, the time to 
morbidity took about 3-7 days longer with tumor initiation from cultured cells than from 
tumor pieces (personal observation). 
 
The intracerebral VM-M2, VM-M3, and VM-NM1 tumors were also examined using Iba1 
immunohistochemistry (Figure 3).  Iba1 is an established marker for 
microglia/macrophages (Ohsawa et al. 2000; Sasaki et al. 2001; Drage et al. 2002). It is 
clear that the invasive VM-M2 tumor cells expressed Iba1 and were largely protoplasmic 
in morphology (Figure 3).  This is in marked contrast to the VM-NM1 tumor cells, which 
did not express Iba1.  The VM-M3 tumor stained with Iba1 appeared the same as that of 
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the VM-M2 tumor.  The Iba1 positive cells in the VM-NM1 tumor are derived from host 
infiltrating cells rather than from the tumor cells and expressed a ramified morphology 
similar to that seen in microglia from epileptic mouse brain (Drage et al. 2002).   
 
When grown s.c., the VM-M2 and the VM-M3 tumors metastasized to multiple organ 
systems (lung, liver, spleen, kidney, and brain) (Figure 4 & 5).  Cells from the VM-M2 
and VM-M3 tumors metastasized to form numerous secondary tumor nodules in the 
liver and the spleen (Figure 4).  The latency for gross visual appearance of metastatic 
nodules in various organs was 3-4 weeks for the VM-M2 tumor and was 2-3 weeks for 
the VM-M3 tumor, consistent with the differences in growth rate between these two 
tumors.  Spleen size was noticeably larger in mice bearing the VM-M2 and VM-M3 
tumors than in mice bearing the VM-NM1 tumor (Figure 4).  The micro-metastatic 
lesions of the VM-M2 and the VM-M3 tumors were examined using H&E staining and 
Iba1 immunohistochemistry (Figure 5).  Our results show that the tumor cells identified 
with H&E staining corresponded exactly with the Iba1 positive cells in kidney, lung, 
brain, and liver.  These data suggest that the tumor cells identified with H&E staining 
also stain positive for Iba1. The micro-metastatic lesions were widely disseminated 
throughout the kidney, lung, and liver, but were localized largely to the meninges in 
brain.  The spleen was not shown because the metastatic lesions were diffusely 
disseminated throughout the organ.  No metastatic cells or secondary tumor nodules 
were found in any organ of mice bearing the VM-NM1 tumor.  The morphology and size 
of the liver and the spleen from VM-NM1-tumor bearing mice appeared the same as 
that of normal non-tumor bearing mice (Figure 4). 
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The VM-M3 tumor cells were transduced with a lentiviral vector expressing firefly 
luciferase (M3/Fluc) to track tumor growth and spread in vivo (Figures 6-9).  All 
mice implanted s.c. and i.c. with M3/Fluc tumor tissue developed observable 
metastasis within 14 days of implantation, as indicated by formation of secondary 
bioluminescent regions (Figure 6 and 8).  Total mouse bioluminescence 
increased markedly within 7 days of tumor cell implantation (Figure 7 and 9).  
Mice implanted s.c. were sacrificed on day 23 and the liver, lung, kidneys, 
spleen, and brain were imaged ex vivo as described in Materials and Methods 
(Figure 7).  All five organs contained M3/Fluc tumor cells, with lung and liver 
containing the greatest bioluminescence.  Mice implanted i.c. were sacrificed on 
day 15 and the liver, lung, kidneys and spleen were imaged ex vivo (Figure 9). 
The lung and liver contained the most M3/Fluc tumor cells.  In addition, the whole 
brain containing the M3/Fluc tumor was removed and cut down the midline and 
imaged as described in the Materials and Methods.  This allowed for the 
quantiation of the primary tumor as well as invasion into the contralateral 
hemisphere (Figure 10).  Taken together, these findings indicate that the VM-M2 
and VM-M3 cells express all of the features of metastatic cancer to include local 
invasion, intravasation, immune system survival, extravasation, and secondary 
tumor formation. 
 
In contrast to the VM-M2 and the VM-M3 tumors, neither local tissue invasion nor 
metastasis was observed for the VM-NM1 tumor following s.c. or i.c. implantation 
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(Figures 2C, 4, and 5).  Additionally, no metastatic lesions were found in any 
organ examined for mice bearing the VM-NM1 tumor using H&E or Iba1 staining 
(Figure 5).  The rapid growth rate of the VM-NM1 tumor caused morbidity within 
14 days of s.c. implantation due to large tumor size.  A flank grown VM-NM1 
tumor was also surgically resected to reduce size.  While this debulked tumor 
grew in the flank for a longer period of time (28 days) than the metastatic VM-M3 
tumor (24 days), no evidence of metastasis was found in any organ upon 
necropsy.  In another experiment, we reduced by half the number of VM-NM1 
tumor pieces implanted s.c. to delay time to morbidity.  This reduced the tumor 
mass and also allowed the VM-NM1 tumor to grow in the VM mice for the same 
length of time as that seen for the metastatic VM-M3 tumor.  No evidence of 
metastatic spread to any organ was observed from the VM-NM1 tumor despite 
the increased growth period.  Moreover, the VM-NM1 tumor grew in the flank as 
an encapsulated mass and did not invade the underlying muscle tissue.  A 
similar growth pattern for the VM-NM1 tumor was also apparent in the brain 
where a sharp boundary was seen between the tumor mass and the surrounding 
brain tissue (Figure 2C).  These findings indicated that the VM-NM1 tumor is not 
metastatic/invasive regardless of how long it grows in vivo. The VM-NM1 tumor 
growth pattern was in marked contrast to that observed for the metastatic VM-M2 
and VM-M3 tumors, which degraded the underlying musculature, were not 
encapsulated, and invaded extensively into the brain parenchyma.  
 
In vitro morphology, adhesion, and phagocytic behavior 
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Since the VM tumor cells arose in the brain and the VM-M2 and VM-M3 tumor 
cells had macrophage characteristics, the cultured VM tumor cells were 
compared to the astrocyte C8-D30 cell line (AC) and the macrophage RAW 
264.7 cell line.  The morphological appearance of the VM-M2 and the VM-M3 
cells were similar to each other and to that of the RAW 264.7 cells (Figure 11).  
Each of these cell lines expressed mixed morphology consisting of large flat cells 
with protoplasmic extensions (arrows) and small round haloed cells.  The mixed 
morphology of these cells was not due to the presence of multiple cell types in 
these cultures, but rather to single cells that changed their morphology during the 
cell cycle.  For example, prior to dividing, a large flat cell formed into a small 
round haloed cell, divided, and then transformed into a large flat cell (Figure 11).  
In contrast, the VM-NM1 and the AC cells expressed a uniform spindle shaped 
morphology that remained relatively constant throughout the cell cycle as shown 
in Figure 11.  The VM-M2, the VM-M3 and the RAW 264.7 cells were strongly 
adhesive to the tissue culture flask and were resistant to trypsin treatment.  
Scraping was necessary to remove these cells from the flask.  In contrast, the 
VM-NM1 cells and the AC cells were susceptible to trypsin treatment and were 
easily removed from the culture flask without scraping. 
 
Phagocytosis of fluorescent beads was noticeably greater in the VM-M2, the VM-
M3 and the RAW 264.7 cells than in the VM-NM1 and the AC cells (Figure 12).  
In contrast to the VM-M2, the VM-M3 and the RAW 264.7 cells, in which most 
fluorescent beads were internalized, most of the fluorescent beads associated 
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with the VM-NM1 and the AC cells remained on the cell surface.  These findings 
indicate that the VM-M2 and the VM-M3 cells were more similar to the RAW 
264.7 cells than to the AC cells with respect to morphology, adhesion, and 
phagocytic behavior.  On the other hand, these properties in the VM-NM1 cells 
were more similar to those of the AC cells. 
 
Gene expression profiles 
Based on the differences in behavior, the expression of genes characteristic of 
macrophages, glia, neurons, and neural stem/progenitor cells were examined in 
the various cell lines.  The genes characteristic of macrophages included CD11b 
(an adhesive integrin), Iba1 (a calcium binding protein), F4/80 (an antigen), CD68 
(a glycoprotein that binds to low density lipoprotein), CD45 (a protein tyrosine 
phosphatase) and CXCR4 (a chemokine receptor) (Guillemin and Brew 2004).  
These macrophage genes are also expressed in microglia, the resident 
macrophages of brain (Guillemin and Brew 2004).  The genes characteristic of 
neurons and glia included glial fibrillary acidic protein (GFAP; an intermediate 
filament protein) and NF200 (a neurofilament), respectively (Eng 1985; 
Trojanowski et al. 1986).  The genes characteristic of neural stem/progenitor 
cells included nestin (an intermediate filament protein) and sialyltransferase II 
(SAT II) (Seyfried and Yu 1985b; Lendahl et al. 1990; Yanagisawa et al. 2005).  
In general, the expression of macrophage-type genes was restricted to the VM-
M2, the VM-M3 and the RAW 264.7 cells (Figures 13A and 14), whereas 
expression of the neural stem/progenitor-type genes was restricted to the VM-
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NM1 cells (Figure 13B).  The AC cells also expressed the nestin gene, but not 
the SATII gene.  None of the VM tumor cell lines expressed genes for mature 
astrocytes (GFAP) or neurons (NF200) (Figure 13B).  Also, none of the VM 
tumor cell lines expressed CD19 (a cell surface protein), a gene characteristic of 
B cells. (Engel et al. 1995).  Viewed together, these findings indicate that gene 
expression in the two metastatic VM tumor cell lines was similar to that in the 
RAW 264.7 cells and differed markedly from that in the non-metastatic VM-NM1 
and the AC cells.  
 
Iba1 expression 
Iba1 gene and protein expression was analyzed in the VM tumor cells and in 
control cell lines as described in the Materials and Methods.  Iba1 was heavily 
expressed in the VM-M2, VM-M3 and RAW cells, but was mostly undetectable in 
the VM-NM1 cells and the AC cells (Figure 14).  These findings support the 
microglial/macrophage origin of the metastatic VM-M2, VM-M3 tumor cells. 
 
Lipid Distribution 
Lipids were evaluated because these molecules can provide specific information 
on cell origin, function, and behavior.  In general, the distribution of neutral and 
acidic lipids was more similar in the VM-M2, the VM-M3, and the RAW 264.7 
cells than in the VM-NM1 and AC cells (Figures 15 and 16 and Table 2).  This 
was especially noteworthy for sphingomyelin and phosphatidic acid levels, which 
were markedly higher in the VM-M2, the VM-M3, and the RAW 264.7 cells than 
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in the VM-NM1 and the AC cells.  Indeed, the levels of phosphatidic acid were 
about 6 to 7 fold higher in the VM-M2 and the VM-M3 cells than in the VM-NM1 
cells.  The elevated phosphatidic acid levels in the VM-M2 and the VM-M3 cells 
were also associated with reduced levels of phosphatidylcholine relative to the 
VM-NM1 cells, the lipid precursor of phosphatidic acid.   Phosphatidylinositol 
levels were highest in the VM-NM1 and the AC cells, whereas levels of 
cholesterol, cardiolipin, phosphatidylethanolamine and phosphatidylserine were 
generally similar among all the cell lines.  Several lipids were either undetectable 
or found in only trace amounts and included, cholesterol esters, triglycerides, 
ceramide, lysophosphatidylcholine, cerebrosides, and sulfatides (Figures 15 and 
16 and Table II).  
 
In addition to the markedly similar distribution of phospholipids in the VM-M2, the 
VM-M3 and the RAW 264.7 cells, these three lines also expressed significant 
amounts of the neutral glycosphingolipid asialo-GM1 (GA1) (Figure 17).  GA1 is 
enriched in macrophages and is a reliable marker for tumor-associated 
macrophages (Ecsedy et al. 1998a).  GA1 was undetectable in the VM-NM1 and 
AC cells.  
 
The distribution of gangliosides was markedly similar in the VM-M2, the VM-M3, 
and the RAW 264.7 cells, in which GM1 and GD1a were the major species 
(Figure 18 and Table II).  These gangliosides migrated as double bands due to 
structural heterogeneity of molecular species (El-Abbadi et al. 2001).  
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Ganglioside GM3 was undetectable in these cells.  In contrast, GM3 was the 
major ganglioside expressed in the VM-NM1 cells, and was the only ganglioside 
detectable in AC cells.  The VM-NM1 cells also expressed GD1a, GM2, GM1, 
and GD3.  GD3 expression is interesting because this ganglioside is a marker for 
stem cells or cells of neural progenitor origin (Seyfried and Yu 1985b; 
Yanagisawa et al. 2005).  GD3 was not expressed in the VM-M2, the VM-M3, or 
the RAW 264.7 cells.  None of the cell lines expressed gangliosides (GT1b and 
GQ1b) characteristic of neurons.  Viewed together, these findings indicate that 
the distribution of total lipids in the two metastatic VM tumor cell lines was similar 
to that of the RAW 264.7 cells and was different from that of the non-metastatic 
VM-NM1 cells and from the AC cells. 
 
Gene expression of glycosynapse 3 components 
In order to determine if the components of glycosynapse 3 were present in the 
VM cell lines, the expression of tetraspanin CD9, and the alpha5, alpha3 and 
beta1 integrins were examined.  The metastatic VM-M2 and VM-M3 cells 
expressed the genes for CD9, alpha5 and beta1 but did not express the gene for 
alpha3 (Figure 19).  The non-metastatic VM-NM1 cells expressed the genes for 
CD9, alpha5, alpha3 and beta1 (Figure 19).  While the metastatic cells did not 
express the gene for the alpha3 integrin, they did express the genes for the 
alpha5 and beta1 integrins, suggesting that the VM-M2 and VM-M3 cells can 
form the alpha5beta1 complex. This complex could interact with CD9 in the 
presence of GM3 to form a surrogate glycosynapse 3 complex with alpha5beta1 
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substituting for alpha3beta1 since GM3 has been previously shown to interact 
with alpha5beta1 (Wang et al. 2003). 
 
MMP9 expression 
The gene for MMP9 was expressed in the VM-M2, VM-M3 and the VM-NM1 
cells.  However, MMP9 expression levels were higher in the metastatic VM-M2 
and VM-M3 cells when compared to the non-metastatic VM-NM1 cells (Figure 
20). 
 
GalNAc-T knockdown and ganglioside GM3 upregulation 
M3/Fluc tumor cells express the gene for GalNAc-T, a key enzyme for complex 
ganglioside biosynthesis, and therefore contain the complex gangliosides GM2, 
GM1, and GD1a as the major gangliosides, with no detectable levels of the 
simple ganglioside GM3 (Figures 18 and Table III).  To further investigate the 
role of GM3 on the invasion and metastatic properties of the M3/Fluc tumor, 
ganglioside distribution was altered through the knockdown of the GalNAc-T 
gene to produce expression of ganglioside GM3 in the M3/Fluc tumor cells.  The 
lentiviral vector, pLKO.1-puro, containing a DNA sequence that forms a short-
hairpin RNA structure upon transcription that targets the GalNAc-T gene, was 
stably transduced into the M3/Fluc cells (Fluc-TNG; Figure 23).  M3/Fluc tumor 
cells were also stably transduced with the pLKO.1-puro lentiviral vector 
containing a DNA sequence that forms a short-hairpin RNA structure with no 
known homology to any mouse DNA sequence (Fluc-csh; Figure 23).  These 
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short hairpin RNA structures act as double-stranded RNA and activate the RNAi 
pathway (Paddison et al. 2002).  Therefore, the Fluc-csh cell line was used as a 
control for the infection of a lentiviral vector and the activation of the RNAi 
pathway without the knockdown of a gene.  Clonal cell lines were produced from 
the stable transfectants.  RT-PCR and QRT-PCR were used to examine GalNAc-
T expression in the M3/Fluc, Fluc-csh, and Fluc-TNG cell lines.  The relative 
expression GalNAc-T in the Fluc-csh was approximately the same of that of the 
M3/Fluc cells (Figure 24).  In contrast, the relative expression of GalNAc-T in the 
Fluc-TNG cells was only 15% of that of the M3/Fluc (Figure 24).  These data 
indicate that the stable transduction of the shRNA GalNAc-T lentiviral vector 
significantly knocked-down GalNAc-T gene expression in the Fluc-TNG cells 
while the control lentiviral vector did not significantly affect GalNAc-T gene 
expression in the Fluc-csh cells.  In addition, expression of the GM3 synthase 
gene, the enzyme upstream in the ganglioside biosynthetic pathway, was 
significantly higher in the Fluc-TNG cells when compared to the control cell lines 
(Figure 24). 
 
Differential GalNAc-T expression in the various Fluc cell lines was correlated with 
differences in ganglioside GM3 levels as detected by HPTLC autoradiogram.  
The M3/Fluc and Fluc-csh cells expressed similar levels of GalNAc-T and had no 
detectable levels of GM3 with slight differences in complex ganglioside 
distributions (Figure 25 and Table III).  In contrast, the Fluc-TNG cells that had a 
85% reduction in GalNAc-T expression level, had an increase in GM3 content, 
 37 
resulting in the Fluc-TNG cells containing 9% GM3, 2% GM2, 39% GM1, and 
50% GD1a (Figures 22 and 23 and Table III).  
 
In vitro growth rates and morphology of the Fluc-csh and Fluc-TNG cells 
There was no significant difference in the in vitro growth rates for the M3/Fluc, 
Fluc-csh, and Fluc-TNG cell lines over 96 hours (Figure 26).  Additionally, there 
was no difference in morphology for the M3/Fluc, Fluc-csh, and Fluc-TNG cells 
lines. 
 
In vivo invasive behavior of the Fluc-csh and Fluc-TNG tumors 
VM mice were implanted with either the Fluc-csh or the Fluc-TNG tumor i.c. as 
described in the Materials and Methods.  While there was no difference in the in 
vitro growth rates of the Fluc-csh and the Fluc-TNG tumor cells, the time to 
morbidity was 13 days for mice bearing the Fluc-csh tumor and 15 days for mice 
bearing the Fluc-TNG tumor intracerebrally.  The difference in morbidity for these 
two groups resulted in larger primary tumors for mice bearing the Fluc-TNG 
tumors when compared to those bearing the Fluc-csh tumors (Figure 27A).  
However despite the larger primary tumor, invasion into the contralateral 
hemisphere was significantly reduced in the brains containing the Fluc-TNG 
tumor when compared to those containing the Fluc-csh tumor (Figure 27B). 
 
The Fluc-csh tumor was diffusely invasive into the neural parenchyma showing 
multiple tumor foci in the hippocampal region well in advance of the main tumor 
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mass (Figure 28).  The Fluc-csh tumor cells invaded through the hippocampal 
region (arrows, Figure 28) and overlying cerebral cortex with many areas 
exhibiting streams of invading tumor cells (arrow heads, Figure 28).  This was 
similar to that seen in the VM-M2, VM-M3, and the M3/Fluc tumors.  In contrast 
to the Fluc-csh tumor, the Fluc-TNG tumor was non-invasive and formed a sharp 
boundary between the main tumor mass and the neural parenchyma similar to 
that seen in the VM-NM1 tumor (Figure 28).  No tumor foci in advance of the 
main tumor mass were detected in any brains containing the Fluc-TNG tumor.  In 
addition, while the Fluc-TNG tumor was non-invasive, it was still highly 
malignant.  These findings indicate that the Fluc-TNG tumor differed markedly 
from the control Fluc-csh tumor with respect to time to morbidity and invasive 
behavior.  
 
The Fluc-csh tumor was chosen as a more parsimonious control for the invasion 
and metastasis experiments (see below) due to the differences in ganglioside 
content and time to morbidity between the Fluc-csh and M3/Fluc tumors.  The 
difference in time to morbidity is likely due to differences in in vivo passage 
number between the Fluc-csh and M3/Fluc tumors as the growth properties of 
these tumors changes slightly over time (personal observation). 
 
Metastatic behavior of the Fluc-csh and Fluc-TNG tumors 
VM mice were implanted with either the Fluc-csh or the Fluc-TNG tumor in the 
flank as described in the Materials and Methods.  Growth and metastatic spread 
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of the s.c. implanted tumors was tracked in vivo with bioluminescence imaging. 
The latency for observable secondary bioluminescent regions was 21 days for 
the Fluc-csh tumor (Figure 29).  While, no secondary bioluminescent regions 
were detectable in mice bearing the Fluc-TNG tumor before the mice reached 
morbitdity (Figure 29).  Both groups of mice were sacrificed at morbidity.  Mice 
bearing the Fluc-csh and Fluc-TNG tumors were sacrificed 28 and 30 days post 
implantation, respectively, and the liver, lung, kidneys, spleen, and brain were 
imaged ex vivo as described in the materials and methods (Figure 30 and Table 
III).  Of the mice bearing the Fluc-csh tumor, 100 percent had detectable 
metastasis to the liver and lung and 67 percent had metastasis to the spleen as 
detected by bioluminescent cells in these organs (n=9; Table III).  In contrast, of 
the mice bearing the Fluc-TNG tumor only 23 percent had detectable metastasis 
to the liver and 54 percent had metastasis to the lung (n=13; Table III).  None of 
the Fluc-TNG tumor bearing mice had detectable metastasis to the spleen.  
Additionally, there was no detectable metastasis to the kidney or the brain in 
either the Fluc-csh or Fluc-TNG tumor bearing mice (Table III).   
 
The organs that had detectable metastasis in both the Fluc-csh and Fluc-TNG 
groups were quantified and plotted on a linear scale (Figure 30).  Metastasis to 
liver and lung was significantly lower in mice bearing the Fluc-TNG tumor with no 
detectable spread to spleen compared to the organs from mice bearing the Fluc-
csh tumor as indicated by lower bioluminescent values in these organs (p<0.05, 
Figure 30).  These findings indicate that the Fluc-TNG tumor bearing mice had 
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fewer incidences of metastasis to liver and lung, and spleen when compared to 
those bearing the Fluc-csh tumor (Table III).  Additionally, when the Fluc-TNG 
tumor did metastasize, the amount of tumor cells present in the organs was 
significantly lower than organs from mice bearing the Fluc-csh tumor (Figure 30).    
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Figure 1.  Growth curve for the VM-M2, VM-M3, and VM-NM1 tumor cells grown 
in vitro.  Values are expressed as the means of ten independent samples ± SEM. 
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Figure 2.  Intracerebral growth of VM tumors.   
Tumors were implanted into the cerebral cortex of VM mice as described in the 
Materials and Methods.  The VM-M2, VM-M3, and VM-NM1 tumors shown were similar 
in size and were grown for 28, 18 and 8 days, respectively.  The black and white boxes 
in the lower power (50X) images in the top row are shown at higher power (630X) in the 
middle row and bottom row, respectively.  The VM-M2 tumor cells are shown invading 
through the hippocampal CA2 region and overlying cerebral cortex (A) and the VM-M3 
tumor cells are shown invading as streams through the cerebral cortex (arrowhead, B).  
Both the VM-M2 and VM-M3 tumors formed multiple tumor foci in advance of the main 
tumor mass in the hippocampal molecular layer (arrows, A & B).  Many of these 
advanced tumor foci formed perivascular pseudorossets (D & E).  The VM-M2 and VM-
M3 tumor cells were pleomorphic with hyperchromatic nuclei (G & H).  The VM-NM1 
tumor was non-invasive and displayed a clear boundary between the tumor and the 
neural paranchemya (C).  No tumor foci or perivascular pseudorossets were detected in 
the VM-NM1 tumor (C & F).  The VM-NM1 cells were more homogeneous than that of 
the VM-M2 and VM-M3 cells (I).  CA1, CA2, and CA3 identify the main hippocampal 
pyramidal layers.  DG, designates the dentate gyrus and T, designates tumor tissue.  
The scale bars shown in the first column are the same for all images in that row.  
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Figure 3.   Iba-1 immunostaining of VM-M2 and VM-NM1 tumors grown i.c.  Sections 
from the VM-M2 and VM-NM1 tumors analyzed in Figure 1 were stained for Iba1 as 
described in the Materials and Methods.  The black boxes in the lower power (100X) 
images in the top row are shown in higher power (630X) in the bottom row.  The cells of 
the VM-M2 main tumor mass and those invading into the neural parenchyma were Iba-1 
positive.  The Iba-1 positive cells in the VM-NM1 tumor do not correspond to tumor cells 
but represent the tumor-infiltrating macrophages.  Three independent mice were 
analyzed for each tumor. 
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Figure 4.  Appearance of liver and spleen from mice bearing VM tumors. 
Tumors were implanted subcutaneously in the flank as described in Materials and 
Methods.  The livers and spleens shown here were from mice bearing the VM-M2, the 
VM-M3, and the VM-NM1 tumors that were grown subcutaneously for 40 days, 24 days 
and 14 days, respectively.  Cells from the VM-M2 and VM-M3 tumors metastasized to 
form numerous secondary tumor nodules in the liver and the spleen.  Spleen size was 
noticeably larger in mice bearing the VM-M2 and VM-M3 tumors than in mice bearing 
the VM-NM1 tumor.  No metastatic cells or secondary tumor nodules were found in the 
liver or the spleen of mice bearing the VM-NM1 tumor.  The morphology and size of the 
liver and the spleen from VM-NM1-tumor bearing mice appeared the same as that of 
normal (non-tumor bearing) mice (not shown).  
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Figure 5.  Appearance of micrometastatic lesions in mice bearing VM tumors.  H&E and 
Iba-1 staining revealed numerous micro-metastatic lesions in the brain, kidney, lung, 
and liver in mice bearing the VM-M2 tumor.  The black boxes in the lower power images 
(100X) in the top two rows are shown at higher power (400X) in the bottom two rows. 
The distribution, morphology, and staining of the micro-metastatic lesions in mice 
bearing the VM-M3 appeared the same as that of the mice bearing the VM-M2 tumor 
(not shown).  At least three independent mice were analyzed for each tumor. 
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Figure 6.  Subcutaneous growth and metastatic spread of M3/Fluc tumor detected with 
bioluminescence imaging.  Tumors were implanted s.c in the flank as described in 
Materials and Methods.  Multiple metastases were detected in vivo following 
implantation.  Dorsal (upper panels) images were taken over 23 days and ventral (lower 
panels) images were taken once metastasis was detectable (representative mouse 
shown).   
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Figure 7.  Quantitation of subcutaneous growth and metastatic spread of M3/Fluc 
tumor.  Bioluminescence from the whole mouse (dorsal and ventral images added 
together) was quantified and plotted on a log scale (A).  Liver, lung, kidneys, spleen, 
and brain were imaged 23 days after implantation ex vivo and metastasis was quantified 
as described in Materials and Methods (B).  Values are expressed as means ± SEM for 
6 independent mice. 
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Figure 8.  Intracerebral growth and metastatic spread of M3/Fluc tumor detected with 
bioluminescence imaging.  Tumors were implanted i.c. in the brain as described in 
Materials and Methods.  Multiple metastases were detected in vivo 13 day after 
implantation.  Dorsal (upper panels) images were taken over 15 days and ventral (lower 
panels) images were taken after day 9 (representative mouse shown).   
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Figure 9.  Quantitation of intracerebral growth and metastatic spread of M3/Fluc tumor. 
Bioluminescence from the whole mouse (dorsal and ventral images added together) 
was quantified and plotted on a log scale (A).  Liver, lung, kidneys and spleen were 
imaged 15 days after implantation ex vivo and metastasis was quantified as described 
in Materials and Methods (B).  Values are expressed as means ± SEM for 5 
independent mice. 
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Figure 10.  Intracerebral growth and contralateral invasion of the M3/Fluc tumor 
detected with bioluminescence imaging.  Tumors were implanted into the 
cerebral cortex of the VM mice as described in the Materials and Methods.  Mice 
were sacrificed at morbidity.  Tumor growth in the ipsilateral hemisphere and 
invasion to the contralateral hemisphere were measured and quantified on a log 
scale + SEM for 6 independent mice.  Representative photographs and merged 
bioluminescent images are shown below. 
 60 
 
 
 61 
Figure 11.  In vitro morphology of VM tumors and control cell lines.  Cells were 
grown to approximately 50% confluency under identical culture conditions as 
described in Materials and Methods.  The VM-M2, the VM-M3, and the RAW 
267.4 cells appeared as either large flat cells with protoplasmic extensions 
(arrows) or as small round haloed cells.  The VM-NM1 and the AC cells 
expressed a uniform spindle shape. 
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Figure 12.  Phagocytic behavior of VM tumor and control cell lines.  Phagocytic 
behavior was assessed from merging (Merge) the fluorescence (F) images and the 
differential interference contrast (DIC) images. The fluorescent beads were engulfed 
(phagocytosis) in the VM-M2, the VM-M3, and the RAW 264.7 cells, but remained 
largely on the surface of the VM-NM1 and the AC cells.  
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Figure 13.   Expression of genes characteristic of macrophages and neural cells in VM 
tumor cells and control cell lines.  Gene expression was assessed in cells grown under 
identical culture conditions using semi-quantitative RT-PCR as described in the 
Materials and Methods.  A battery of genes characteristic of macrophages were 
expressed in the VM-M2, VM-M3, and the RAW 264.7 cells, but their expression was 
undetectable in the VM-NM1 or the AC cells (A).  The expression genes characteristic 
of neural cells was undetectable in the VM-M2, VM-M3 and RAW 264.7 cells (B).   
Genes characteristic of neural progenitor/stem cells (nestin and SAT II) were expressed 
in the VM-NM1 cells.  The AC cells expressed nestin and the gene characteristic of 
mature astrocytes (GFAP).  The NF200 gene (expressed in mature neurons) and CD19 
(expressed in B cells) were undetectable in all the cell lines.   C, designates control 
tissue.  Embryonic brain was used for nestin and SAT II, adult brain for GFAP and 
NF200, and spleen for CD19.  β-actin was used as a control. 
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Figure 14. Iba1 expression in VM tumor and control cell lines.  (A) Protein expression 
was analyzed by western blot and was quantified as described in the Materials and 
Methods. (B) Iba1 gene expression was analyzed by QRT-PCR and was quantified as 
described in the Materials and Methods. All values are expressed as the means ± SEM 
for 3 independent samples. 
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Figure 15.  High-performance thin-layer chromatogram of neutral phospholipids in VM 
tumor and control cell lines. The amount of neutral lipids spotted on the HPTLC for each 
cell line was equivalent to approximately 70 µg cell dry weight.  The individual neutral 
phospholipids bands were visualized by charring with the cupric acetate, phosphoric 
acid solution. The abbreviations used on the HPTLC plates for the neutral and acidic 
lipid plates were as follows: Std, purified lipid standards; B, VM mouse brain; CE, 
cholesterol esters; TG, triglycerides; IS, internal standard (oleyl alcohol); C, cholesterol; 
CM, ceramide; CB, cerebrosides (doublet); PE, phosphatidylethanolamine; PC, 
phosphatidylcholine; SPM, sphingomyelin; O, origin; SF, solvent front of the first 
developing solvent system.  2-4 independent samples were analyzed for each group. 
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Figure 16. High-performance thin-layer chromatogram of acidic phospholipids in VM 
tumor and control cell lines.  The amount of acidic lipids spotted on the HPTLC for each 
cell lines were equivalent to approximately 400 µg of cell dry weight. The individual 
acidic phospholipid bands were visualized by charring with the cupric acetate, 
phosphoric acid solution. The abbreviations used on the HPTLC plates for the neutral 
and acidic lipid plates were as follows: Std, purified lipid standards; B, VM mouse brain; 
O, origin; SF, solvent front of the first developing solvent system; CL, cardiolipin; PA, 
phosphatidic acid; Sulf, sulfatides (doublet); PS, phosphatidylserine; and PI, 
phosphatidylinositol.  
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Figure 17.  Thin-layer chromatogram of asialo-GM1 (GA1) in VM tumor and control cell 
lines.  For GA1 analysis, approximately 2 mg of cell dry weight were spotted for each 
cell line and visualized following immunostaining with anti-GA1 antibody. 
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Figure 18.  High-performance thin-layer chromatogram of gangliosides in VM tumor and 
control cell lines.  Approximately 3000 dpms of radiolabeled gangliosides were spotted 
on the HPTLC for each cell line and the individual gangliosides were visualized as an 
autoradiogram.  The ganglioside standards on this plate were from VM mouse brain, B, 
and purified GM3 and were visualized with the resorcinol spray.  The individual 
gangliosides were labeled according to the nomenclature system of Svennerholm 
(Svennerholm 1963). 
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Figure 19.  Expression of genes involved in the formation of glycosynapse 3 in VM 
tumor cells.  Gene expression was assessed in cells grown in vitro using semi-
quantitative RT-PCR as described in the Materials and Methods.  The expression of 
CD9, and integrins alpha 5 and beta1 were expressed in all the cell lines.  Integrin 
alpha3 was expressed in the VM-NM1 cells and was undetectable in the metastatic VM-
M2 and VM-M3 cell lines.  β-actin was used as a control.  Representative samples 
shown (n=4). 
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Figure 20.  Expression of MMP9 in the VM tumor cell lines.  Gene expression was 
assessed in cells grown in vitro using semi-quantitative RT-PCR as described in the 
Materials and Methods.  MMP9 expression was markedly higher in the metastatic VM-
M2 and VM-M3 cells when compared to the non-metastatic VM-NM1 cells. β-actin was 
used as a control.  Representative samples shown (n=4). 
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Figure 21.  Ganglioside GM3 structure and orientation in the plasma membrane.  
The lipophilic ceramide portion inserts into the plasma membrane while the 
oligosaccharide head group containing glucose (Glc), galactose (Gal), and sialic 
acid (SA) molecules project into the extracellular environment. 
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Figure 22.  Glycosphingolipid biosynthetic pathways.  Ceramide is the substrate 
for the synthesis of all GSLs, including gangliosides.  Ganglioside biosynthesis 
continues by the action of multiple glycosyltransferases and sialytransferases, 
where the product of one enzymatic reaction serves as the substrate for the next 
enzymatic reaction.  Three major metabolic pathways, the “a”, “b”, and “c” 
pathways are responsible for the synthesis of gangliosides.  In addition, the 
“asialo” pathway is responsible for the neutral GSLs.   Abbreviations:  Glc, 
glucose; Gal, galactose; GalNAc, N-acetylgalactoseamine; SA- sialic acid; Gal-T, 
galactoseyltransferase; GalNAc-T, beta-1,4-N-acetylgalactosaminyl transferase; 
and ST, sialytransferase. 
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Figure 23.  Lentiviral plasmid vector pLKO.1-puro map and features.  The 
pLKO.1-puro plasmid was used for the insertion of both the control short hairpin 
RNA sequence and the short hairpin RNA sequence targeting the GalNAc-T 
gene. 
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Figure 24.  Expression of GM3 synthase and GalNAc-T in the M3/Fluc, Fluc-csh, 
and Fluc-TNG cell lines.  Gene expression was assessed in cells grown under 
identical culture conditions using semi-quantitative RT-PCR (A and B) and 
quantitative real-time PCR (C) as described in the Materials and Methods.  PCR 
was performed using β-actin as an internal control.  Values are expressed as the 
means of four independent samples ± SEM.  *Significant compared with control 
M3/Fluc and Fluc-csh cells at the p<0.001 level. 
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Figure 25.  High-performance thin-layer chromatogram of gangliosides in 
M3/Fluc, Fluc-csh, and Fluc-TNG cell lines.  Approximately 3000 dpm of 
radiolabeled gangliosides were spotted on the HPTLC for each cell line and the 
individual gangliosides were visualized as an autoradiogram.  The ganglioside 
standards on this plate were from VM mouse brain, B, and purified GM3 and 
were visualized with the resorcinol spray.  The individual gangliosides were 
labeled according to the nomenclature system of Svennerholm (Svennerholm 
1963). 
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Figure 26. Growth curve for the M3/Fluc, Fluc-csh, and Fluc-TNG tumor cells grown in 
vitro.  Values are expressed as the means of ten independent samples ± SEM. 
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Figure 27.  Intracerebral growth and contralateral invasion of the Fluc-csh and 
Fluc-TNG tumors detected with bioluminescence imaging.  Tumors were 
implanted i.c. right cerebral hemisphere (ipsilateral) as described in the Materials 
and Methods.  Mice were sacrificed at morbidity and the tumor containing brains 
were removed and cut down the midline.  The ipsilateral and contralateral 
hemispheres were imaged 13 days and 15 days post implantation for the Fluc-
csh and Fluc-TNG tumor bearing mice respectively.   Primary tumor growth (A) 
and invasion to the contralateral hemisphere (B) were measured by 
bioluminescence imaging and quantified on a linear scale + SEM.  The 
bioluminescence photon scale is the same for both the Fluc-csh and Fluc-TNG 
tumors.  Representative bioluminescent brain hemispheres are shown.  The 
asterisk indicates that the amount of Fluc-TNG tumor invasion is significantly less 
than the amount of invasion of the Fluc-csh tumor into the contralateral 
hemisphere at the p<0.001 level. 
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Figure 28.  Intracerebral growth and invasion of the Fluc-csh and the Fluc-TNG tumors 
examined with H&E.  Tumors were implanted into the cerebral cortex of VM mice as 
described in the Materials and Methods.  Mice were sacrificed at morbidity.  The Fluc-
csh and Fluc-TNG tumors shown were allowed to grow for 13 and 15 days, respectively.  
The Fluc-csh tumors are shown forming perivascular pseudorossetes in the 
hippocampal region (arrows) and Fluc-csh tumor cells are shown invading as streams 
through the cerebral cortex (arrowheads).  The Fluc-TNG tumor was non-invasive and 
displayed a clear boundary between the tumor and the neural paranchemya, similar to 
that seen in the VM-NM1 tumor (Figure 2C).  The tumors shown here are representative 
samples from the bioluminescent images and quantitation seen in Figure 27.  The scale 
bar shown in the first panel is the same for both images. 
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Figure 29.  Subcutaneous growth and metastatic spread of the Fluc-csh and the 
Fluc-TNG tumors detected with bioluminescence imaging.  Tumors were 
implanted s.c. in the flank as described in Materials and Methods. Mice were 
sacrificed at morbidity.  The Fluc-csh and Fluc-TNG tumors were allowed to grow 
for 28 and 30 days, respectively.  The Fluc-csh tumor displayed multiple 
metastases following implantation.  The Fluc-TNG tumor appeared to grow as a 
malignant solid tumor with reduced metastatic spread.  The bioluminescence 
photon scale is the same for both the Fluc-csh and Fluc-TNG tumors.  Dorsal 
(upper panels) images were taken over 28-30 days and ventral (lower panels) 
images were taken after 14 days post implantation.  Representative mice shown. 
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Figure 30.  Quantitation of metastatic lesions in mice bearing the Fluc-csh and 
the Fluc-TNG tumors detected with bioluminescence imaging.  Upon morbidity, 
mice bearing the s.c. Fluc-csh and Fluc-TNG tumors were sacrificed and liver, 
lung, and spleen were imaged ex vivo 28 and 30 days after implantation, 
respectively, and metastasis was quantified as described in Materials and 
Methods.  Values are represented as means of 9 and 13 independent mice + 
SEM for Fluc-csh and Fluc-TNG tumors, respectively.   
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Table I.  Wet weight (mg) of VM brain containing i.c. tumors a 
 
 
 
 
a Weights taken 9 days post implantation. 
b Values represent the mean of three independent samples + SEM. 
*  VM-NM1 containing brain weighs significantly more than the VM-M3 containing 
brain p<0.01. 
Sham  388 + 13b 
VM-NM1   522 + 32 * 
VM-M3 409 + 15 
 102 
Table II:  Lipid distributions in metastatic and non-metastatic cell lines a 
 
Table II: Lipid distributions in metastatic and non-metastatic cell lines a 
a Values represent percentages of individual lipids and are expressed as means 
± SEM of 3-4 independent samples from each cell line except for VM-M2 where 
two independent samples are listed. 
b,The percentage distributions for neutral lipids, acidic lipids, and gangliosides 
were generated from the densitometric scanning of HPTLC plates similar to 
those shown in Figure 4A, 4B, and 4C, respectively. 
c ND= not detectable. 
Cell Line 
Lipidb M2 M3 RAW NM1 AC 
      
Neutral Lipids      
Cholesterol (C) 24, 38 37 ± 8 39 ± 6 33 ± 2 43 ± 6  
Ceramide (CM) trace trace trace  trace trace 
Phosphatidylethanolamine (PE) 21, 19 21 ± 1 17 ± 1  10 ± 1 16 ± 1 
Phosphatidylcholine (PC) 28, 37 25 ± 8 23 ± 4 45 ± 1  33 ± 5 
Sphingomyelin (SPM) 13, 17 16 ± 1 20 ± 1   7 ± 1   6 ± 1  
      
Acidic Lipids       
Cardiolipin (CL) 17, 18 13 ± 1 15 ± 1 17 ± 1  14 ± 1 
Phosphatidic Acid (PA) 32, 31 27 ± 1 12 ± 1   4 ± 1   7 ± 1 
Phosphatidylserine (PS) 21, 22 25 ± 2 30 ± 1 32 ± 1 27 ± 1 
Phosphatidylinositol (PI) 27, 28 34 ± 2 43 ± 1  46 ± 2 51 ± 2 
      
Gangliosides      
GM3 ND c ND ND 61 ± 3 99 ± 1 
GM2 3, 2   4 ± 1   4 ± 1   2 ± 1 trace 
GM1 50, 52 58 ± 2 51 ± 2   5 ± 1 trace 
GD3 ND ND ND   2 ± 1 trace 
GD1a 47, 46 38 ± 2 45 ± 2 30 ± 2 trace 
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Table III:  Ganglioside distributions in Fluc-TNG and control cell lines a 
 Cell Line 
Ganglioside b M3/Fluc Fluc-csh Fluc-TNG 
    
GM3 ND c ND   9 + 1 
GM2   2 + 1   6 + 1   2 + 1 
GM1 37 + 4 49 + 3 39 + 2 
GD1a 61 + 5 44 + 3 51 + 2 
 
a Values represent percentages of individual gangliosides and are expressed as 
means + SEM of 4 independent samples from each cell line. 
b The percentage distribution was generated from the densitometric scanning of 
HPTLC plates similar to that shown in Figure 25. 
c ND= not detectable. 
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Table IV:  Percent of animals with metastasis to organs a 
Tumor N Liver Lung Spleen 
  Fluc-csh 9 100 100 67 
  Fluc-TNG 13  23* 54 0* 
a The presence of metastasis was detected with bioluminescence imaging. 
* The asterisk indicates that the Fluc-TNG group is significantly less than the 
Fluc-csh group as calculated by chi square analysis at the p<0.05 level. 
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DISCUSSION 
 
Our findings show that the autochthonously arising VM-M2 and VM-M3 tumors 
expressed all the major biological processes of metastasis to include local invasion, 
intravasation, immune system survival, extravasation, and secondary tumor formation.  
The selection of these tumors in their orthotopic site in vivo, rather than selection as 
cultured cells in vitro, may have contributed to the development and discovery of their 
highly metastatic phenotype (Khanna and Hunter 2005).  Following s.c. implantation, 
the VM-M2 and the VM-M3 tumors metastasized to all major organ systems (liver, 
kidney, spleen, and lung) and are the only known experimental mouse tumors that 
reliably metastasize to brain (Khanna and Hunter 2005; Weil et al. 2005).  An advantage 
of the metastatic VM tumors over other metastatic mouse models is that every VM 
mouse bearing a subcutaneous VM-M2 or VM-M3 tumor developed widespread 
systemic metastasis within a relatively short period of time (~ 4 weeks).  Another 
advantage is that the syngeneic host strain used for metastatic tumor growth (inbred VM 
mice) has a functional immune system.  Hence, the metastatic VM tumors provide a 
quick and reliable system for modeling all the major biological steps of cancer 
metastasis in a natural host environment. 
 
Although the metastatic VM-M2 and VM-M3 tumors arose in the brains of VM mice, they 
did not express genes or lipid markers characteristic of mature neurons (NF200, and 
complex gangliosides GT1b and GQ1b), astrocytes (GFAP and ganglioside GM3) or 
oligodendrocytes (cerebrosides and sulfatides) (Eng et al. 1971; Raff et al. 1978; 
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Seyfried et al. 1983; Trojanowski et al. 1986; Asou et al. 1989).  The absence of CD19 
gene expression argues against an origin from lymphocytes.  The VM-M2 and VM-M3 
tumors also did not express the neural stem/progenitor cell markers for nestin, 
ganglioside GD3, or SAT II, making it unlikely that the VM-M2 and VM-M3 tumors arose 
from neural stem cells or neural progenitor cells (Seyfried and Yu 1985a; Lendahl et al. 
1990). However, nestin, ganglioside GD3 and SATII were expressed in the VM-NM1 
tumor suggesting that this non-metastatic tumor arose from a neural stem/progenitor 
cell.  These findings indicate that spontaneous brain tumors in VM mice can arise from 
different cell types and that the highly invasive and metastatic VM-M2 and VM-M3 
tumors are not of neural origin. 
 
On the other hand, the VM-M2 and the VM-M3 tumor cells expressed several 
morphological, behavioral, and genetic characteristics of macrophages.  For 
example, the metastatic VM tumor cells were strongly adhesive to the culture 
dish and were highly phagocytic.  These are classical properties of macrophages 
(Burke and Lewis 2002b).  Additionally, the in vitro morphology and growth 
characteristics of VM-M2 and VM-M3 cell lines were remarkably similar to those 
of the RAW 264.7 macrophage cell line.   The VM-M2, VM-M3 and RAW 264.7 
cells also expressed multiple genes (CD11b, Iba1, F4/80, CD68, CD45, CXCR4) 
that are expressed in macrophages and microglia, the resident brain 
macrophage (Springer et al. 1979; Austyn and Gordon 1981; Micklem et al. 
1989; Rossi and Zlotnik 2000; Kanazawa et al. 2002; Guillemin and Brew 2004).  
It is unlikely that the expression of these macrophage characteristics in the VM-
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M2 and VM-M3 cell lines resulted from the in vitro culture conditions since none 
of these characteristics were expressed in the VM-NM1 or AC cells that were 
cultured under identical conditions.  Rather, the expression of these macrophage 
properties in the VM-M2 and VM-M3 cell lines indicates that these metastatic 
tumor cells share behavioral, morphological and genetic similarities with tissue 
macrophages and that these cells arose from macrophages.  
 
Further evidence for the macrophage origin of the VM-M2 and VM-M3 tumors comes 
from the analysis of lipid composition.  The VM-M2, VM-M3, and RAW 264.7 cells had 
remarkably similar distributions of phospholipids and glycosphingolipids suggesting that 
these cells share a common origin.  Indeed, the ganglioside pattern of the VM-M2 and 
VM-M3 cells was nearly identical to that of the RAW 264.7 cells.  The elevated levels of 
sphingomyelin and gangliosides GM1 and GD1a together with undetectable GM3 
expression in the VM-M2 and VM-M3 cells is consistent with pro-angiogenic activities 
and phagocytosis involving lipid rafts and caveolin-1 (Iwabuchi et al. 2000; Lugini et al. 
2003; Nichols 2003; Williams and Lisanti 2005; Abate et al. 2006; Lugini et al. 2006).  
High levels of GM3, as seen in the VM-NM1 and AC cells, are associated with cell-cell 
adhesion and reduced angiogenesis (Bai and Seyfried 1997; Abate et al. 2006).  The 
high phosphatidic acid levels in the VM-M2 and VM-M3 cells are intriguing since 
phosphatidic acid is known to participate in key macrophage functions to include 
invasion, phagocytosis, inflammation, and the respiratory burst (McPhail et al. 1995; 
Sliva et al. 2000; Lim et al. 2003; Lugini et al. 2003; Lee et al. 2004; Corrotte et al. 2006; 
Lugini et al. 2006).  These lipid biochemical data add further to our data on behavior, 
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morphology, and gene expression indicating that the VM-M2 and VM-M3 cells express 
characteristics of macrophages or macrophage-like cells.  The VM-M2 and VM-M3 cells 
will serve as an important new model cell system for evaluating the role of lipids in 
metastatic disease.  
 
Macrophages are among the most versatile cells of the body in terms of their ability to 
move, to change shape, and to secrete growth factors and cytokines (Burke and Lewis 
2002b).  In their response to tissue injury or disease, normal macrophages express 
several hallmarks of metastatic tumor cells.  For example, activated macrophages 
extravasate from the circulation into inflamed or diseased tissue where they proliferate 
and establish a microenvironment to facilitate angiogenesis and wound healing.  This 
process involves release of inflammatory cytokines and phagocytosis of debris.  
Following these activities, macrophages intravasate back into the circulation where they 
take up residence in the lymph nodes and participate in the immune response 
(Sunderkotter et al. 1994a; Bellingan et al. 1996; Seyfried 2001b).  Previous studies in 
several human cancers showed that metastatic tumor cells express molecular and 
behavioral characteristics of macrophages (Kerbel et al. 1983; De Baetselier 1984; Ruff 
and Pert 1984; Calvo et al. 1987; Munzarova et al. 1992a; Rachkovsky and Pawelek 
1999; Chakraborty et al. 2001).  Ruff and Pert found that antigens recognized only on 
macrophages (CD36, C3bi, CD11b) were also expressed on tumor cells from human 
small cell lung carcinoma (Ruff and Pert 1984).  Other investigators reported that 
macrophage specific antigens (CD11b, CD14, CD15 and CD45) were found on 
metastatic melanoma and breast carcinoma (Calvo et al. 1987; Munzarova et al. 
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1992a).  Tumor cells from metastatic melanoma, Meth A sarcoma, breast carcinoma, 
and medulloblastoma also display macrophage-like activity with respect to invasive 
behavior, chemotactic mobility, and phagocytosis (Youness et al. 1980; Montcourrier et 
al. 1994; Busund et al. 2003; Lugini et al. 2003; Ghoneum and Gollapudi 2004; Lugini et 
al. 2006).  Considered together, these findings suggest that some metastatic human 
cancers might arise from macrophages or macrophage-like cells.  
 
Although macrophages or macrophage-like cells have long been proposed as the origin 
of several human metastatic cancers, this hypothesis has not been widely accepted or 
recognized (Nowell 1976; Fidler and Kripke 1977; Fidler and Hart 1982; Hanahan and 
Weinberg 2000; Pawelek 2000; Fidler 2003; Pawelek 2005).  Rather, macrophages are 
generally considered part of the tumor stroma that either inhibit or facilitate tumor 
growth (Seyfried 2001b; Lewis and Murdoch 2005; Luo et al. 2006).  Difficulty in 
accepting the macrophage hypothesis of metastatic cancer has been due in part to its 
reliance on a fusion hybrid mechanism whereby metastatic cancer cells arise following 
hybridization between macrophages or between macrophages and other cells 
(Munzarova and Kovarik 1987; Munzarova et al. 1992a; Pawelek 2000; Duelli and 
Lazebnik 2003; Pawelek 2005; Vignery 2005).  This proposed mechanism of cancer 
metastasis stands apart from more widely recognized mechanisms involving somatic 
mutations and epithelial-mesenchymal transitions (Nowell 1976; Fidler and Kripke 1977; 
Fidler and Hart 1982; Hanahan and Weinberg 2000; Thiery 2002; Fidler 2003; Yang et 
al. 2004).  While I have not addressed the potential mechanism by which the different 
spontaneous VM tumors arose in the VM mice, our results with the VM metastatic 
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tumors provide the strongest and most comprehensive evidence to date supporting the 
hypothesis that metastatic cancer cells can arise from macrophages or macrophage-like 
cells.   
 
A macrophage origin of invasive and metastatic tumors could explain numerous 
previous findings of macrophage properties expressed by tumor cells.  The possibility 
that some metastatic cancers represent a macrophage disease would have important 
implications for cancer diagnosis and therapy.  The VM tumor model system will have 
considerable utility for better defining the major biological processes of cancer 
metastasis and for evaluating potential therapies that can target these processes for 
tumor management. 
 
These data demonstrate that a gene-linked shift in ganglioside distribution significantly 
influenced invasion and metastasis in the highly invasive and metastatic mouse M3/Fluc 
tumor.  Specifically, the knockdown of GalNAc-T expression in the M3/Fluc tumor cells 
produced a shift in the distribution of gangliosides synthesized through the “a” metabolic 
pathway.  This resulted in an elevation of GM3 content and changes in the percent 
distribution of the complex gangliosides GM1 and GD1a.  These results support 
previous findings showing that genetic manipulation of the ganglioside biosynthetic 
enzymes to include GalNAc-T, alters the ganglioside composition and distribution in a 
variety of cell types (Aoki et al. 2004; Abate et al. 2006).  For example, renal cell 
carcinoma and astrocytoma cells transfected with either short interfering RNA (siRNA) 
targeting or an antisense construct targeting the GalNAc-T gene, significantly reduced 
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the GalNAc-T mRNA, resulting in an up-regulation of ganglioside GM3 (Aoki et al. 2004; 
Abate et al. 2006).  Additionally, the transfection of GalNAc-T cDNA induced 
biosynthesis of the complex gangliosides GM2, GM1, and GD1a and reduced 
ganglioside GM3 in an experimental mouse brain tumor (Manfredi et al. 1999).  These 
findings indicate that GM3 content can be modulated through manipulation of GalNAc-T 
gene expression.  Additionally, the knockdown of GalNAc-T affected the expression of 
other glycosyltransferases within the “a” metabolic pathway.  Since the end product of a 
ganglioside pathway regulates the expression of biosynthetic enzymes within the same 
pathway, it is possible that the changes in glycosyltransferase expression reflect the 
changes seen in the ganglioside distribution (Yusuf et al. 1987; Abate et al. 2006).   
 
The effects of GM3 on tumor cell proliferation are under debate.  For example, GM3 has 
been shown to reduce both human and mouse brain tumor cell proliferation in vitro and 
in vivo.   (Zeng et al. 2000; Noll et al. 2001; Abate et al. 2006).  However, GM3 has also 
previously been shown to have no effect on renal cell carcinoma proliferation (Aoki et al. 
2004).  In order to elucidate the role of GM3 in M3/Fluc tumor cell proliferation, the 
growth rates of the Fluc-csh and Fluc-TNG tumors were analyzed both in vitro and in 
vivo.  The gene-linked up-regulation of GM3 in the M3/Fluc cells did not reduce the rate 
of tumor growth.  Specifically, the in vitro growth rate of the GM3 containing Fluc-TNG 
cells did not differ significantly from either of the control cell lines (M3/Fluc and Fluc-
csh).  Additionally, in vivo, the time to morbidity for mice bearing the Fluc-TNG tumors 
either i.c. or s.c. was 48 hours longer than mice bearing Fluc-csh tumors.  The 
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difference in time to morbidity for the Fluc-TNG tumors compared to the Fluc-csh 
tumors may be due to the reduction of invasive behavior. 
 
Although the relationship between GM3 and tumor cell invasion is complicated, my 
findings in the M3/Fluc tumor can provide new insight into this phenomenon.  It has 
been previously established for different tumor types that either transient knockdown of 
GalNAc-T or exogenous addition of GM3 reduces tumor cell invasion in vitro. 
(Kawamura et al. 2001; Noll et al. 2001; Ono et al. 2001; Fujimoto et al. 2005).  
Additionally, the exogenous addition of GM3 reduces glioma cell invasion in vivo 
(Fujimoto et al. 2005).  Yet, the effects of endogenous up-regulation of GM3 on tumor 
cell invasion in vivo have not yet been determined.  However, by the use of a lentiviral 
vector and shRNA, the knockdown of GalNAc-T in the Fluc-TNG cells produced an 
endogenous up-regulation of GM3 that was stable over time.  Utilizing a novel in vivo 
invasion assay, I was able to determine for the first time that the gene-linked up-
regulation of GM3 reduced M3/Fluc invasiveness in vivo.  The elevation of GM3 in the 
Fluc-TNG cells significantly inhibited tumor cell invasion to the contralateral hemisphere 
of the brain in mice bearing the Fluc-TNG tumor when compared to mice bearing the 
Fluc-csh tumor i.c.  These findings support previous work showing that GM3 has anti-
invasive properties and provides new evidence that GM3 is also anti-invasive in vivo 
when endogenously up-regulated. 
 
Since the stable up-regulation of GM3 in the M3/Fluc cells was successful, I was 
able to examine the effects of GM3 on metastasis.  This up-regulation of GM3 
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had an effect on the metastatic phenotype of the M3/Fluc cells.  The M3/Fluc 
cells containing GM3 (Fluc-TNG) had a lower frequency of metastasis to major 
organs when compared to the control M3/Fluc cells that did not contain GM3 
(Fluc-csh).  Additionally, when the GM3 containing M3/Fluc tumors did 
metastasize, the number of tumor cells in the distant organs was significantly 
lower than organs containing tumor cells from the control tumor as indicated by 
lower bioluminescence values in liver and lung.  Therefore, the presence of GM3 
in the M3/Fluc cells reduced both the frequency and amount of metastasis in 
mice bearing the M3/Fluc tumors.  These findings indicate that the presence of 
GM3 reduces the metastatic ability of the M3/Fluc tumor and supports previous 
findings that GM3 is present in non-invasive and non-metastatic tumors and 
reduced in highly invasive and metastatic tumors (Kawamura et al. 2001; Ono et 
al. 2001; Mitsuzuka et al. 2005; Huysentruyt et al. 2008; Pawelek and 
Chakraborty 2008).   
 
Although it is unclear how GM3 inhibits the invasion and metastasis of the 
M3/Fluc tumor, there are several interesting mechanisms that could underlie this 
phenomenon.  The presence of GM3 in the Fluc-TNG cells could be interacting 
with the alpha5beta1 integrin and tetraspanin CD9, inducing the formation of the 
microdomain glycosynapse 3.  The formation of glycosynapse 3 would increase 
the adhesive properties of the M3/Fluc cells and consequently reduce mobility 
and invasion (Wang et al. 2003; Mitsuzuka et al. 2005).  Additionally, GM3 has 
been shown to reduce CD9-facilitated cell motility, a tetraspanin that is 
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expressed in all VM tumors (Ono et al. 2001).  GM3 has also been shown to 
reduce the expression and activation of the matrix metalloproteinase-9 (MMP9) 
through effects on epithelial growth factor receptor signaling (Wang et al. 2003).  
MMP9 is a metalloproteinase that degrades several extracellular matrix proteins 
to include fibronectin, lamin, gelatin, and collagen and is expressed in epithelial 
cells and over expressed in many types of metastatic cancer (Wang et al. 2003; 
Mendes et al. 2005; Zhang et al. 2006).   Additionally, MMP9 is highly expressed 
in the VM-M2 and VM-M3 tumors.   It is also possible that GM3 affects the 
macrophage/microglial properties of the M3/Fluc cells.   Upon macrophage 
activation, GM3 levels are reduced with a corresponding increase in migratory 
and phagocytic behaviors.  Therefore, an increase in GM3 in the M3/Fluc cells 
could be influencing the activated phenotype of the M3/Fluc cells (Cohn 1978; 
Yohe et al. 1985b; Macala and Yohe 1995; Yohe et al. 1997; Ecsedy et al. 
1998b; Carbonell et al. 2005).  Further studies will be needed to investigate the 
potential mechanisms by which GM3 is having an anti-invasive and an anti-
metastatic effect.   
 
Taken together, these findings show that an elevation of GM3 in the M3/Fluc 
tumor significantly influences invasion and metastasis.  Moreover, this suggests 
that the distribution and content of the simple ganglioside GM3 is important for 
tumor progression and malignancy.  Since gangliosides influence many aspects 
of tumor progression such as proliferation, angiogenesis, invasion and 
metastasis, gangliosides are potential targets for the management of various 
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types of cancer.  The VM tumor model system will have considerable utility for 
better defining the roles of gangliosides in metastasis and for evaluating potential 
therapies that can target these processes for tumor management. 
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CONCLUSION 
 
Metastasis, the spread of cancer cells from the primary tumor site to distant 
organs, has been extensively studied for many years.  However, the process of 
how a cell acquires a metastatic phenotype is still under debate (Hanahan and 
Weinberg 2000; Christiansen and Rajasekaran 2006; Huysentruyt et al. 2008; 
Pawelek and Chakraborty 2008; Yang and Weinberg 2008).  Traditionally, it is 
believed that metastatic cancer cells arise from pre-existing tumor cells that have 
undergone additional genetic alterations during the late stages of tumor 
progression.  Nowell first proposed that neoplastic progression occurs through 
acquired genetic variability within individual tumor cells along with selective 
pressures resulting in clones with a growth advantage and increased malignancy 
(Nowell 1976).  One way this is believed to occur is through the activation of 
transcription factors which initiate the epithelial-mesenchymal transition (EMT) 
(Yang et al. 2004; Yang et al. 2006).  The EMT program is a highly conserved 
process that is frequently observed during embryogenesis and development that 
enables the conversion of epithelial cells into mesenchymal cells.  Hence, the 
acquired ability to migrate and invade the extracellular matrix through clonal 
evolution is the hallmark of the EMT (Berx et al. 2007; Yang and Weinberg 
2008).  However, the clonal evolution of cancer has yet to be proven 
(Christiansen and Rajasekaran 2006). 
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Interestingly, macrophages have long been proposed to be the origin of many 
human metastatic cancers however, this theory has not been widely accepted.  
Instead, macrophages are thought to be part of the tumor stroma that either 
facilitate or inhibit tumor growth (Seyfried 2001a; Vignery 2005; Lewis and 
Pollard 2006; Mantovani et al. 2006; Talmadge et al. 2007).  Many of the 
previous studies supporting the macrophage hypothesis of metastatic cancer 
have focused on a fusion hybrid mechanism whereby metastatic cancer cells 
arise following hybridization between macrophages or between macrophages 
and other cells (Munzarova and Kovarik 1987; Munzarova et al. 1992b; Pawelek 
2000, 2005).  In 1911, Aichel first proposed that malignancy could arise from the 
fusion between a macrophage and a somatic cell (reviewed in (Pawelek and 
Chakraborty 2008).  This theory was expanded upon 60 years later when Mekler 
included hybrids between macrophages and primary tumor cells (reviewed in 
(Pawelek and Chakraborty 2008).  Warner in 1975 further proposed that 
hybridization within tumors promotes the genomic and phenotypic diversity seen 
within many tumor types (Warner 1975).  Since then, several studies in murine 
and human cancers have reported that metastatic tumor cells express molecular 
and behavioral characteristics of macrophages, further supporting the 
macrophage origin of metastatic cancer (Ruff and Pert 1984; Calvo et al. 1987; 
Munzarova et al. 1992a; Rachkovsky et al. 1998; Huysentruyt et al. 2008; 
Pawelek and Chakraborty 2008).   
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My thesis research provides new evidence for the theory of a macrophage origin 
of cancer.  While developing a novel mouse model of systemic metastatic 
cancer, I was able to determine that the metastatic VM-M3 and VM-M3 cancer 
cells were similar to macrophages with respect to morphological, behavioral, 
genetic and biochemical properties.  Suggesting, that the highly invasive and 
metastatic VM-M2 and VM-M3 tumors were of macrophage origin.  As 
macrophages are mesenchymal cells, my findings support a mesenchymal 
association with metastatic cancer.  However for the VM-M2 and VM-M3 tumors, 
it is difficult to conceive how random genetic mutations could transform an 
epithelial cell into a metastatic cell with morphological, behavioral, genetic and 
biochemical properties of macrophages.  The non-invasive and non-metastatic 
VM-NM1 tumor that did not express any macrophage properties but did express 
properties of a neural stem cell.   
 
Additionally, my thesis research shows that invasion and metastasis can be altered 
through changes in GM3 content.  Here I show that a gene-linked up-regulation of GM3 
in the M3/Fluc cells results in a significant reduction of the invasive and metastatic 
phenotype of the M3/Fluc tumor.  This was demonstrated through the use of a novel in 
vivo invasion assay and the VM tumor model system that were developed through the 
course of my thesis research.  While experiments using transient up-regulation of GM3 
or exogenous addition of GM3 showed increased tumor cell adhesion and reduced 
invasion, the effects of long-term endogenous GM3 up-regulation in vivo were 
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previously unknown (Zeng et al. 1995; Mukherjee et al. 2004).  This model will be useful 
for evaluating the use of GM3 as a potential therapy for metastatic cancer. 
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